

115TH CONGRESS
2D SESSION

S. 2680

To address the opioid crisis.

IN THE SENATE OF THE UNITED STATES

APRIL 16, 2018

Mr. ALEXANDER (for himself and Mrs. MURRAY) introduced the following bill;
which was read twice and referred to the Committee on Health, Edu-
cation, Labor, and Pensions

A BILL

To address the opioid crisis.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the
5 “Opioid Crisis Response Act of 2018”.

6 (b) TABLE OF CONTENTS.—The table of contents of
7 this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—REAUTHORIZATION OF CURES FUNDING

Sec. 101. State response to the opioid abuse crisis.

TITLE II—RESEARCH AND INNOVATION

Sec. 201. Advancing cutting-edge research.

Sec. 202. Pain research.

TITLE III—MEDICAL PRODUCTS AND CONTROLLED SUBSTANCES SAFETY

- Sec. 301. Clarifying FDA regulation of non-addictive pain products.
- Sec. 302. Clarifying FDA packaging authorities.
- Sec. 303. Strengthening FDA and CBP coordination and capacity.
- Sec. 304. Clarifying FDA post-market authorities.
- Sec. 305. First responder training.
- Sec. 306. Disposal of controlled substances of a deceased hospice patient by employees of a hospice program.
- Sec. 307. GAO study and report on hospice safe drug management.
- Sec. 308. Delivery of a controlled substance by a pharmacy to be administered by injection, implantation, or intrathecal pump.

TITLE IV—TREATMENT AND RECOVERY

- Sec. 401. Comprehensive opioid recovery centers.
- Sec. 402. Program to support coordination and continuation of care for drug overdose patients.
- Sec. 403. Alternatives to opioids.
- Sec. 404. Peer support technical assistance.
- Sec. 405. Medication-assisted treatment for recovery from addiction.
- Sec. 406. National recovery housing best practices.
- Sec. 407. Addressing economic and workforce impacts of the opioid crisis.
- Sec. 408. Youth prevention and recovery.
- Sec. 409. Plans of safe care.
- Sec. 410. Regulations relating to special registration for telemedicine.
- Sec. 411. National Health Service Corps behavioral and mental health professionals providing obligated service in schools and other community-based settings.
- Sec. 412. Loan repayment for substance use disorder treatment providers.
- Sec. 413. Improving treatment for pregnant and postpartum women.
- Sec. 414. Early interventions for pregnant women and infants.

TITLE V—PREVENTION

- Sec. 501. Study on prescribing limits.
- Sec. 502. Programs for health care workforce.
- Sec. 503. Education and awareness campaigns.
- Sec. 504. Enhanced controlled substance overdoses data collection, analysis, and dissemination.
- Sec. 505. Preventing overdoses of controlled substances.
- Sec. 506. CDC surveillance and data collection for child, youth, and adult trauma.
- Sec. 507. Reauthorization of NASPER.
- Sec. 508. Jessie's Law.
- Sec. 509. Development and dissemination of model training programs for substance use disorder patient records.
- Sec. 510. Communication with families during emergencies.
- Sec. 511. Prenatal and postnatal health.
- Sec. 512. Surveillance and education regarding infections associated with injection drug use and other risk factors.
- Sec. 513. Task force to develop best practices for trauma-informed identification, referral, and support.

Sec. 514. Grants to improve trauma support services and mental health care
for children and youth in educational settings.

Sec. 515. National Child Traumatic Stress Initiative.

1 TITLE I—REAUTHORIZATION OF 2 CURES FUNDING

3 SEC. 101. STATE RESPONSE TO THE OPIOID ABUSE CRISIS.

4 (a) IN GENERAL.—Section 1003 of the 21st Century
5 Cures Act (Public Law 114–255) is amended—

6 (1) in subsection (a)—

7 (A) by striking “the authorization of ap-
8 propriations under subsection (b) to carry out
9 the grant program described in subsection (c)”
10 and inserting “subsection (h) to carry out the
11 grant program described in subsection (b)”;
12 and

13 (B) by inserting after “and Indian tribes”
14 after “States”;

15 (2) by striking subsection (b);

16 (3) by redesignating subsections (c) through (e)
17 as subsections (b) through (d), respectively;

18 (4) by redesignating subsection (f) as sub-
19 section (j);

20 (5) in subsection (b), as so redesignated—

21 (A) in paragraph (1)—

22 (i) in the paragraph heading, by in-
23 serting “AND INDIAN TRIBE” after
24 “STATE”;

(ii) by striking “States for the purpose of addressing the opioid abuse crisis within such States” and inserting “States and Indian tribes for the purpose of addressing the opioid abuse crisis within such States and Indian tribes”;

(iii) by inserting “or Indian tribes” after “preference to States”; and

(iv) by inserting before the period of the second sentence “or other Indian tribes, as applicable”; and

(B) in paragraph (2)—

(i) in the matter preceding subparagraph (A), by striking “to a State”;

(ii) in subparagraph (A), by striking “State”;

(iii) in subparagraph (C), by inserting “preventing diversion of controlled substances,” after “treatment programs,”; and

(iv) in subparagraph (E), by striking “as the State determines appropriate, related to addressing the opioid abuse crisis within the State” and inserting “as the State or Indian tribe determines appro-

1 priate, related to addressing the opioid
 2 abuse crisis within the State, including di-
 3 recting resources in accordance with local
 4 needs related to substance use disorders”;

5 (6) in subsection (c), as so redesignated, by
 6 striking “subsection (c)” and inserting “subsection
 7 (b)”;

8 (7) in subsection (d), as so redesignated—

9 (A) in the matter preceding paragraph (1),
 10 by striking “the authorization of appropriations
 11 under subsection (b)” and inserting “subsection
 12 (h)”;

13 (B) in paragraph (1), by striking “sub-
 14 section (c)” and inserting “subsection (b)”;

15 (8) by inserting after subsection (d), as so re-
 16 designated, the following:

17 “(e) INDIAN TRIBES.—

18 “(1) DEFINITION.—For purposes of this sec-
 19 tion, the term ‘Indian tribe’ has the meaning given
 20 such term in section 4 of the Indian Self-Determina-
 21 tion and Education Assistance Act (25 U.S.C.
 22 5304).

23 “(2) APPROPRIATE MECHANISMS.—The Sec-
 24 retary, in consultation with Indian tribes, shall iden-
 25 tify and establish appropriate mechanisms for tribes

1 to demonstrate or report the information as required
2 under subsections (b), (c), and (d).

3 “(f) REPORT TO CONGRESS.—Not later than 1 year
4 after the date on which amounts are first awarded, after
5 the date of enactment of the Opioid Crisis Response Act
6 of 2018, pursuant to subsection (b), and annually there-
7 after, the Secretary shall submit to the Committee on
8 Health, Education, Labor, and Pensions of the Senate and
9 the Committee on Energy and Commerce of the House
10 of Representatives a report summarizing the information
11 provided to the Secretary in reports made pursuant to
12 subsection (c), including the purposes for which grant
13 funds are awarded under this section and the activities
14 of such grant recipients.

15 “(g) TECHNICAL ASSISTANCE.—The Secretary, in-
16 cluding through the Tribal Training and Technical Assist-
17 ance Center of the Substance Abuse and Mental Health
18 Services Administration, shall provide State agencies and
19 Indian tribes, as applicable, with technical assistance con-
20 cerning grant application and submission procedures
21 under this section, award management activities, and en-
22 hancing outreach and direct support to rural and under-
23 served communities and providers in addressing the opioid
24 crisis.

1 “(h) AUTHORIZATION OF APPROPRIATIONS.—For
 2 purposes of carrying out the grant program under sub-
 3 section (b), there are authorized to be appropriated
 4 \$500,000,000 for each of fiscal years 2019 through 2021,
 5 to remain available until expended.

6 “(i) SET ASIDE.—Of the amounts made available for
 7 each fiscal year to award grants under subsection (b) for
 8 a fiscal year, 5 percent of such amount for such fiscal year
 9 shall be made available to Indian tribes, and up to 15 per-
 10 cent of such amount for such fiscal year may be set aside
 11 for States with the highest age-adjusted mortality rate as-
 12 sociated with opioid use disorders based on the ordinal
 13 ranking of States according to the age-adjusted overdose
 14 mortality rates of the Centers for Disease Control and
 15 Prevention.”.

16 (b) PREVIOUSLY APPROPRIATED AMOUNTS.—

17 (1) APPROPRIATION OF AMOUNTS REMAINING
 18 IN ACCOUNT.—Any unobligated amounts remaining,
 19 on the date of enactment of this Act, in the Account
 20 For the State Response to the Opioid Abuse Crisis
 21 established under section 1003(b) of the 21st Cen-
 22 tury Cures Act (Public Law 114–255) (as in effect
 23 on the day before the date of enactment of this Act)
 24 are hereby appropriated to the Secretary of Health
 25 and Human Services for purposes of carrying out

1 the grant program under subsection (b) of section
 2 1003 of the 21st Century Cures Act (Public Law
 3 114–255) (as redesignated by subsection (a)(3) of
 4 this section).

5 (2) AVAILABLE UNTIL EXPENDED.—Amounts
 6 appropriated under paragraph (1) of this subsection
 7 or section 1003(b)(3) of the 21st Century Cures Act
 8 (as in effect on the day before the date of enactment
 9 of this Act) shall remain available until expended.

10 (c) CONFORMING AMENDMENT.—Section 1004(c) of
 11 the 21st Century Cures Act (Public Law 114–255) is
 12 amended by striking “, the FDA Innovation Account, or
 13 the Account For the State Response to the Opioid Abuse
 14 Crisis” and inserting “or the FDA Innovation Account”.

15 **TITLE II—RESEARCH AND** 16 **INNOVATION**

17 **SEC. 201. ADVANCING CUTTING-EDGE RESEARCH.**

18 Section 402(n)(1) of the Public Health Service Act
 19 (42 U.S.C. 282(n)(1)) is amended—

20 (1) in subparagraph (A), by striking “or”;

21 (2) in subparagraph (B), by striking the period
 22 and inserting “; or”; and

23 (3) by adding at the end the following:

24 “(C) high impact cutting-edge research
 25 that fosters scientific creativity and increases

1 fundamental biological understanding leading to
2 the prevention, diagnosis, or treatment of dis-
3 eases and disorders, or research urgently re-
4 quired to respond to a public health threat.”.

5 **SEC. 202. PAIN RESEARCH.**

6 Section 409J(b) of the Public Health Service Act (42
7 U.S.C. 284q(b)) is amended—

8 (1) in paragraph (5)—

9 (A) in subparagraph (A), by striking “and
10 treatment of pain and diseases and disorders
11 associated with pain” and inserting “treatment,
12 and management of pain and diseases and dis-
13 orders associated with pain, including informa-
14 tion on best practices for utilization of non-
15 pharmacologic treatments, non-addictive med-
16 ical products, and other drugs approved, or de-
17 vices approved or cleared, by the Food and
18 Drug Administration”;

19 (B) in subparagraph (B), by striking “on
20 the symptoms and causes of pain;” and insert-
21 ing the following: “on—

22 “(i) the symptoms and causes of pain;

23 “(ii) the diagnosis, prevention, treat-
24 ment, and management of pain; and

1 “(iii) risk factors for, and early warn-
 2 ing signs of, substance use disorders; and”;
 3 (C) by striking subparagraphs (C) through
 4 (E) and inserting the following:

5 “(C) make recommendations to the Direc-
 6 tor of NIH—

7 “(i) to ensure that the activities of the
 8 National Institutes of Health and other
 9 Federal agencies are free of unnecessary
 10 duplication of effort;

11 “(ii) on how best to disseminate infor-
 12 mation on pain care; and

13 “(iii) on how to expand partnerships
 14 between public entities and private entities
 15 to expand collaborative, cross-cutting re-
 16 search.”;

17 (2) by redesignating paragraph (6) as para-
 18 graph (7); and

19 (3) by inserting after paragraph (5) the fol-
 20 lowing:

21 “(6) REPORT.—The Director of NIH shall en-
 22 sure that recommendations and actions taken by the
 23 Director with respect to the topics discussed at the
 24 meetings described in paragraph (4) are included in
 25 appropriate reports to Congress.”.

1 **TITLE III—MEDICAL PRODUCTS**
2 **AND CONTROLLED SUB-**
3 **STANCES SAFETY**

4 **SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICT-**
5 **IVE PAIN PRODUCTS.**

6 (a) PUBLIC MEETINGS.—Not later than 1 year after
7 the date of enactment of this Act, the Secretary of Health
8 and Human Services (referred to in this section as the
9 “Secretary”), acting through the Commissioner of Food
10 and Drugs, shall hold not less than one public meeting
11 to address the challenges and barriers of developing non-
12 addictive medical products intended to treat pain or addic-
13 tion, which may include—

14 (1) the manner by which the Secretary may in-
15 corporate the risks of misuse and abuse of a con-
16 trolled substance (as defined in section 102 of the
17 Controlled Substances Act (21 U.S.C. 802) into the
18 risk benefit assessment under section 505(e) of the
19 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
20 355(e)), section 510(k) of such Act (21 U.S.C.
21 360(k)), or section 515(c) of such Act (21 U.S.C.
22 360e(c)), as applicable;

23 (2) the application of novel clinical trial designs
24 (consistent with section 3021 of the 21st Century
25 Cures Act (Public Law 114–255)), use of real world

1 evidence (consistent with section 505F of the Fed-
2 eral Food, Drug, and Cosmetic Act (21 U.S.C.
3 355g)), and use of patient experience data (con-
4 sistent with section 569C of the Federal Food,
5 Drug, and Cosmetic Act (21 U.S.C. 360bbb–8c)) for
6 the development of non-addictive medical products
7 intended to treat pain or addiction;

8 (3) the evidentiary standards and the develop-
9 ment of opioid sparing data for inclusion in the la-
10 beling of medical products; and

11 (4) the application of eligibility criteria under
12 sections 506 and 515B of the Federal Food, Drug,
13 and Cosmetic Act (21 U.S.C. 356, 360e–3) for non-
14 addictive medical products intended to treat pain or
15 addiction.

16 (b) GUIDANCE.—Not less than one year after the
17 public meetings are conducted under subsection (a) the
18 Secretary shall issue one or more final guidance docu-
19 ments, or update existing guidance documents, to help ad-
20 dress challenges to developing non-addictive medical prod-
21 ucts to treat pain or addiction. Such guidance documents
22 shall include information regarding—

23 (1) how the Food and Drug Administration
24 may apply sections 506 and 515B of the Federal
25 Food, Drug, and Cosmetic Act (21 U.S.C. 356,

1 360e–3) to non-addictive medical products intended
2 to treat pain or addiction, including the cir-
3 cumstances under which the Secretary—

4 (A) may apply the eligibility criteria under
5 such sections 506 and 515B to non-opioid or
6 non-addictive medical products intended to
7 treat pain or addiction;

8 (B) considers the risk of addiction of con-
9 trolled substances approved to treat pain when
10 establishing unmet medical need; and

11 (C) considers pain, pain control, or pain
12 management in assessing whether a disease or
13 condition is a serious or life-threatening disease
14 or condition;

15 (2) the methods by which sponsors may evalu-
16 ate acute and chronic pain, endpoints for non-addict-
17 ive medical products intended to treat pain, the
18 manner in which endpoints and evaluations of effi-
19 cacy will be applied across and within review divi-
20 sions, taking into consideration the etiology of the
21 underlying disease, and the manner in which spon-
22 sors may use surrogate endpoints, intermediate
23 endpoints, and real world evidence;

24 (3) the manner in which the Food and Drug
25 Administration will assess evidence to support the

1 inclusion of opioid sparing data in the labeling of
2 non-addictive medical products intended to treat
3 pain, including—

4 (A) data collection methodologies, includ-
5 ing the use of novel clinical trial designs (con-
6 sistent with section 3021 of the 21st Century
7 Cures Act (Public Law 114–255)), and real
8 world evidence (consistent with section 505F of
9 the Federal Food, Drug, and Cosmetic Act (21
10 U.S.C. 355g)), as appropriate, to support prod-
11 uct labeling;

12 (B) ethical considerations of exposing
13 subjects to controlled substances in clinical
14 trials to develop opioid sparing data and consid-
15 erations on data collection methods that reduce
16 harm, which may include the reduction of
17 opioid use as a clinical benefit;

18 (C) endpoints, including primary, sec-
19 ondary, and surrogate endpoints, to evaluate
20 the reduction of opioid use;

21 (D) best practices for communication be-
22 tween sponsors and the agency on the develop-
23 ment of data collection methods, including the
24 initiation of data collection; and

1 (E) the appropriate format to submit such
2 data results to the Secretary; and

3 (4) the circumstances under which the Food
4 and Drug Administration considers misuse and
5 abuse of drugs in making determinations of safety
6 under paragraphs (2) and (4) of subsection (d) of
7 section 505 of the Federal Food, Drug, and Cos-
8 metic Act (21 U.S.C. 355) and in finding that a
9 drug is unsafe under paragraph (1) or (2) of sub-
10 section (e) of such section.

11 (c) DEFINITIONS.—In this section—

12 (1) the term “medical product” means a drug
13 (as defined in section 201(g)(1) of the Federal
14 Food, Drug, and Cosmetic Act (21 U.S.C.
15 321(g)(1))), biological product (as defined in section
16 351(i) of the Public Health Service Act (42 U.S.C.
17 262(i))), or device (as defined in section 201(h) of
18 the Federal Food, Drug, and Cosmetic Act (21
19 U.S.C. 321(h))); and

20 (2) the term “opioid sparing” means reducing,
21 replacing, or avoiding the use of opioids or other
22 controlled substances.

1 **SEC. 302. CLARIFYING FDA PACKAGING AUTHORITIES.**

2 Section 505–1(e) of the Federal Food, Drug, and
3 Cosmetic Act (21 U.S.C. 355–1(e)) is amended by adding
4 at the end the following:

5 “(4) **SERIOUS ADVERSE DRUG EXPERIENCE.**—

6 The Secretary may require a risk evaluation mitiga-
7 tion strategy for a drug for which there is a serious
8 risk of an adverse drug experience described in sub-
9 paragraph (B) or (C) of subsection (b)(1), taking
10 into consideration the factors described in subpara-
11 graphs (C) and (D) of subsection (f)(2), which may
12 include requiring that—

13 “(A) the drug be made available for dis-
14 pensing to certain patients in unit dose pack-
15 aging, packaging that provides a set duration,
16 or other packaging system that the Secretary
17 determines may help mitigate such serious risk;
18 or

19 “(B) the drug be dispensed to certain pa-
20 tients with a safe disposal packaging or safe
21 disposal system for purposes of rendering un-
22 used drugs non-retrievable (as defined in sec-
23 tion 1300.05 of title 21, Code of Federal Regu-
24 lations (or any successor regulation)) if the Sec-
25 retary has determines that such safe disposal
26 packaging or system may help mitigate such se-

1 rious risk and exists in sufficient quantities, in
 2 consultation with other relevant Federal agen-
 3 cies with authorities over drug packaging.”.

4 **SEC. 303. STRENGTHENING FDA AND CBP COORDINATION**
 5 **AND CAPACITY.**

6 (a) IN GENERAL.—The Secretary of Health and
 7 Human Services (referred to in this section as the “Sec-
 8 retary”), acting through the Commissioner of Food and
 9 Drugs, shall coordinate with the Secretary of Homeland
 10 Security to carry out activities related to customs and bor-
 11 der protection and response to illegal controlled substances
 12 and drug imports, including at sites of import (such as
 13 international mail facilities). Such Secretaries may carry
 14 out such activities through a memorandum of under-
 15 standing between the Food and Drug Administration and
 16 the United States Customs and Border Protection.

17 (b) FDA IMPORT FACILITIES AND INSPECTION CA-
 18 PACITY.—In carrying out this section, the Secretary
 19 shall—

20 (1) in collaboration with the Secretary of
 21 Homeland Security and the Postmaster General of
 22 the United States Postal Service, provide that im-
 23 port facilities in which the Food and Drug Adminis-
 24 tration operates or carries out activities related to

1 drug imports within the international mail facilities
2 include—

3 (A) facility upgrades and improved capac-
4 ity in order to increase and improve inspection
5 and detection capabilities, which may include,
6 as the Secretary determines appropriate—

7 (i) improvements to facilities, such as
8 upgrades or renovations, and support for
9 the maintenance of existing import facili-
10 ties and sites to improve coordination be-
11 tween Federal agencies;

12 (ii) the construction of, or upgrades
13 to, laboratory capacity for purposes of de-
14 tection and testing of imported goods;

15 (iii) upgrades to the security of import
16 facilities; and

17 (iv) innovative technology and equip-
18 ment to facilitate improved and near-real-
19 time information sharing between the Food
20 and Drug Administration, the Department
21 of Homeland Security, and the United
22 States Postal Service; and

23 (B) provide import facilities in which the
24 Food and Drug Administration operates or car-
25 ries out activities related to drug imports within

1 the international mail facilities with innovative
2 technology, including controlled substance de-
3 tection and testing equipment and other appli-
4 cable technology, and collaborate with United
5 States Customs and Border Protection to share
6 near-real-time information, including informa-
7 tion about test results, as appropriate, provided
8 that such technology is interoperable with tech-
9 nology used by other relevant Federal agencies,
10 including the United States Customs and Bor-
11 der Protection, as applicable, and is used in the
12 time and manner that the Secretary determines
13 appropriate.

14 (c) REPORT.—Not later than 6 months after the date
15 of enactment of this Act, the Secretary, in consultation
16 with the Secretary of Homeland Security and the Post-
17 master General of the United States Postal Service, shall
18 report to the relevant committees of Congress on the im-
19 plementation of this section, including a summary of
20 progress made towards near-real-time information sharing
21 and the interoperability of such technologies.

22 (d) AUTHORIZATION OF APPROPRIATIONS.—Out of
23 amounts otherwise available to the Secretary, the Sec-
24 retary may allocate such sums as may be necessary for
25 purposes of carrying out this section.

1 **SEC. 304. CLARIFYING FDA POST-MARKET AUTHORITIES.**

2 Section 505–1(b)(1)(E) of the Federal Food, Drug,
3 and Cosmetic Act (21 U.S.C. 355–1(b)(1)(E)) is amended
4 by striking “of the drug” and inserting “of the drug,
5 which may include reduced effectiveness that is not in ac-
6 cordance with the labeling of such drug”.

7 **SEC. 305. FIRST RESPONDER TRAINING.**

8 Section 546 of the Public Health Service Act (42
9 U.S.C. 290ee–1) is amended—

10 (1) in subsection (c)—

11 (A) in paragraph (2), by striking “and” at
12 the end;

13 (B) in paragraph (3), by striking the pe-
14 riod and inserting “; and”; and

15 (C) by adding at the end the following:

16 “(4) train and provide resources for first re-
17 sponders and members of other key community sec-
18 tors on safety around fentanyl and other dangerous
19 illicit drugs to protect themselves from exposure to
20 fentanyl and respond appropriately when exposure
21 occurs.”;

22 (2) in subsection (d), by inserting “, and safety
23 around fentanyl and other dangerous illicit drugs”
24 before the period;

25 (3) in subsection (f)—

1 (A) in paragraph (3), by striking “and” at
2 the end;

3 (B) in paragraph (4), by striking the pe-
4 riod and inserting a semicolon; and

5 (C) by adding at the end the following:

6 “(5) the number of first responders and mem-
7 bers of other key community sectors trained on safe-
8 ty around fentanyl and other dangerous illicit
9 drugs.”; and

10 (4) in subsection (g), by striking “\$12,000,000
11 for each of fiscal years 2017 through 2021” and in-
12 serting “\$36,000,000 for each of fiscal years 2019
13 through 2023”.

14 **SEC. 306. DISPOSAL OF CONTROLLED SUBSTANCES OF A**
15 **DECEASED HOSPICE PATIENT BY EMPLOY-**
16 **EES OF A HOSPICE PROGRAM.**

17 (a) IN GENERAL.—Section 302(g) of the Controlled
18 Substances Act (21 U.S.C. 822(g)) is amended by adding
19 at the end the following:

20 “(5)(A) An employee of a qualified hospice program
21 acting within the scope of employment may handle, in the
22 place of residence of a hospice patient, any controlled sub-
23 stance that was lawfully dispensed to the hospice patient,
24 for the purpose of assisting in the disposal of the con-
25 trolled substance after the hospice patient’s death.

1 “(B) In this paragraph:

2 “(i) The term ‘employee of a qualified hospice
3 program’ means a physician, physician assistant, or
4 nurse who—

5 “(I) is employed by, or is acting pursuant
6 to arrangements made with, a qualified hospice
7 program; and

8 “(II) is licensed or certified to perform
9 such employment or acts in accordance with ap-
10 plicable State law.

11 “(ii) The terms ‘hospice care’ and ‘hospice pro-
12 gram’ have the meanings given those terms in sec-
13 tion 1861(dd) of the Social Security Act (42 U.S.C.
14 1395x(dd)).

15 “(iii) The term ‘hospice patient’ means an indi-
16 vidual receiving hospice care.

17 “(iv) The term ‘qualified hospice program’
18 means a hospice program that—

19 “(I) has written policies and procedures for
20 employees of the hospice program to use assist-
21 ing in the disposal of the controlled substances
22 of a hospice patient after the hospice patient’s
23 death;

24 “(II) at the time when the controlled sub-
25 stances are first ordered—

1 “(aa) provides a copy of the written
2 policies and procedures to the hospice pa-
3 tient or hospice patient representative and
4 the family of the hospice patient;

5 “(bb) discusses the policies and proce-
6 dures with the hospice patient or hospice
7 patient’s representative and the hospice
8 patient’s family in a language and manner
9 that such individuals understand to ensure
10 that such individuals are informed regard-
11 ing the safe disposal of controlled sub-
12 stances; and

13 “(cc) documents in the clinical record
14 of the hospice patient that the written poli-
15 cies and procedures were provided and dis-
16 cussed with the hospice patient or hospice
17 patient’s representative; and

18 “(III) at the time when an employee of the
19 hospice program assists in the disposal of con-
20 trolled substances of a hospice patient, docu-
21 ments in the clinical record of the hospice pa-
22 tient a list of all controlled substances disposed
23 of.

24 “(C) The Attorney General may, by regulation,
25 include additional types of licensed medical profes-

1 sionals in the definition of the term ‘employee of a
 2 qualified hospice program’ under subparagraph
 3 (B).”.

4 (b) NO REGISTRATION REQUIRED.—Section 302(c)
 5 of the Controlled Substances Act (21 U.S.C. 822(c)) is
 6 amended by adding at the end the following:

7 “(4) An employee of a qualified hospice pro-
 8 gram for the purpose of assisting in the disposal of
 9 a controlled substance in accordance with subsection
 10 (g)(5).”.

11 (c) GUIDANCE.—The Attorney General may issue
 12 guidance to qualified hospice programs to assist the pro-
 13 grams in satisfying the requirements under paragraph (5)
 14 of section 302(g) of the Controlled Substances Act (21
 15 U.S.C. 822(g)), as added by subsection (a).

16 (d) STATE AND LOCAL AUTHORITY.—Nothing in this
 17 section or the amendments made by this section shall be
 18 construed to prevent a State or local government from im-
 19 posing additional controls or restrictions relating to the
 20 regulation of the disposal of controlled substances in hos-
 21 pice care or hospice programs.

22 **SEC. 307. GAO STUDY AND REPORT ON HOSPICE SAFE**
 23 **DRUG MANAGEMENT.**

24 (a) STUDY.—

1 (1) IN GENERAL.—The Comptroller General of
2 the United States (in this section referred to as the
3 “Comptroller General”) shall conduct a study on the
4 requirements applicable to and challenges of hospice
5 programs with regard to the management and dis-
6 posal of controlled substances in the home of an in-
7 dividual.

8 (2) CONTENTS.—In conducting the study under
9 paragraph (1), the Comptroller General shall in-
10 clude—

11 (A) an overview of challenges encountered
12 by hospice programs regarding the disposal of
13 controlled substances, such as opioids, in a
14 home setting, including any key changes in poli-
15 cies, procedures, or best practices for the dis-
16 posal of controlled substances over time; and

17 (B) a description of Federal requirements,
18 including requirements under the Medicare pro-
19 gram, for hospice programs regarding the dis-
20 posal of controlled substances in a home set-
21 ting, and oversight of compliance with those re-
22 quirements.

23 (b) REPORT.—Not later than 18 months after the
24 date of enactment of this Act, the Comptroller General
25 shall submit to Congress a report containing the results

1 of the study conducted under subsection (a), together with
 2 recommendations, if any, for such legislation and adminis-
 3 trative action as the Comptroller General determines ap-
 4 propriate.

5 **SEC. 308. DELIVERY OF A CONTROLLED SUBSTANCE BY A**
 6 **PHARMACY TO BE ADMINISTERED BY INJEC-**
 7 **TION, IMPLANTATION, OR INTRATHECAL**
 8 **PUMP.**

9 (a) IN GENERAL.—The Controlled Substances Act is
 10 amended by inserting after section 309 (21 U.S.C. 829)
 11 the following:

12 “DELIVERY OF A CONTROLLED SUBSTANCE BY A
 13 PHARMACY TO AN ADMINISTERING PRACTITIONER

14 “SEC. 309A. (a) IN GENERAL.—Notwithstanding
 15 section 102(10), a pharmacy may deliver a controlled sub-
 16 stance to a practitioner in accordance with a prescription
 17 that meets the requirements of this title and the regula-
 18 tions issued by the Attorney General under this title, for
 19 the purpose of administering of the controlled substance
 20 by the practitioner if—

21 “(1) the controlled substance is delivered by the
 22 pharmacy to the prescribing practitioner or the prac-
 23 titioner administering the controlled substance, as
 24 applicable, at the location listed on the practitioner’s
 25 certificate of registration issued under this title;

1 “(2)(A) in the case of administering of the con-
2 trolled substance for the purpose of maintenance or
3 detoxification treatment under section 303(g)(2)—

4 “(i) the practitioner who issued the pre-
5 scription is a qualifying practitioner authorized
6 under, and acting within the scope of that sec-
7 tion; and

8 “(ii) the controlled substance is to be ad-
9 ministered by injection or implantation; or

10 “(B) in the case of administering of the con-
11 trolled substance for a purpose other than mainte-
12 nance or detoxification treatment, the controlled
13 substance is to be administered by a practitioner
14 through use of an intrathecal pump;

15 “(3) the pharmacy and the practitioner are au-
16 thorized to conduct the activities specified in this
17 section under the law of the State in which such ac-
18 tivities take place;

19 “(4) the prescription is not issued to supply any
20 practitioner with a stock of controlled substances for
21 the purpose of general dispensing to patients;

22 “(5) except as provided in subsection (b), the
23 controlled substance is to be administered only to
24 the patient named on the prescription not later than

1 14 days after the date of receipt of the controlled
 2 substance by the practitioner; and

3 “(6) notwithstanding any exceptions under sec-
 4 tion 307, the prescribing practitioner, and the prac-
 5 titioner administering the controlled substance, as
 6 applicable, maintain complete and accurate records
 7 of all controlled substances delivered, received, ad-
 8 ministered, or otherwise disposed of under this sec-
 9 tion, including the persons to whom controlled sub-
 10 stances were delivered and such other information as
 11 may be required by regulations of the Attorney Gen-
 12 eral.

13 “(b) MODIFICATION OF NUMBER OF DAYS BEFORE
 14 WHICH CONTROLLED SUBSTANCE SHALL BE ADMINIS-
 15 TERED.—

16 “(1) INITIAL 2-YEAR PERIOD.—During the 2-
 17 year period beginning on the date of enactment of
 18 this section, the Attorney General, in coordination
 19 with the Secretary, may reduce the number of days
 20 described in subsection (a)(5) if the Attorney Gen-
 21 eral determines that such reduction will—

22 “(A) reduce the risk of diversion; or

23 “(B) protect the public health.

24 “(2) MODIFICATIONS AFTER SUBMISSION OF
 25 REPORT.—After the date on which the report de-

1 scribed in subsection (c) is submitted, the Attorney
 2 General, in coordination with the Secretary, may
 3 modify the number of days described in subsection
 4 (a)(5).

5 “(3) MINIMUM NUMBER OF DAYS.—Any modi-
 6 fication under this subsection shall be for a period
 7 of not less than 7 days.”.

8 (b) STUDY AND REPORT.—Not later than 2 years
 9 after the date of enactment of this section, the Comp-
 10 troller General of the United States shall conduct a study
 11 and submit to Congress a report on access to and potential
 12 diversion of controlled substances administered by injec-
 13 tion, implantation, or through the use of an intrathecal
 14 pump.

15 (c) TECHNICAL AND CONFORMING AMENDMENT.—
 16 The table of contents for the Comprehensive Drug Abuse
 17 Prevention and Control Act of 1970 is amended by insert-
 18 ing after the item relating to section 309 the following:

“Sec. 309A. Delivery of a controlled substance by a pharmacy to an admin-
 istering practitioner.”.

19 **TITLE IV—TREATMENT AND** 20 **RECOVERY**

21 **SEC. 401. COMPREHENSIVE OPIOID RECOVERY CENTERS.**

22 (a) IN GENERAL.—Part D of title V of the Public
 23 Health Service Act is amended by adding at the end the
 24 following new section:

1 **“SEC. 550. COMPREHENSIVE OPIOID RECOVERY CENTERS.**

2 “(a) IN GENERAL.—The Secretary, acting through
3 the Assistant Secretary for Mental Health and Substance
4 Use, shall award grants on a competitive basis to eligible
5 entities to establish or operate a comprehensive opioid re-
6 covery center (referred to in this section as a ‘Center’).
7 A Center may be a single entity or an integrated delivery
8 network.

9 “(b) GRANT PERIOD.—

10 “(1) IN GENERAL.—A grant awarded under
11 subsection (a) shall be for a period not more than
12 5 years.

13 “(2) RENEWAL.—A grant awarded under sub-
14 section (a) may be renewed, on a competitive basis,
15 for additional periods of time, as determined by the
16 Secretary. In determining whether to renew a grant
17 under this paragraph, the Secretary shall consider
18 the data submitted under subsection (h).

19 “(c) MINIMUM NUMBER OF GRANTS.—The Secretary
20 shall allocate the amounts made available under sub-
21 section (j) such that not fewer than 10 grants may be
22 awarded. Not more than one grant shall be made to enti-
23 ties in a single State for any one period.

24 “(d) APPLICATION.—In order to be eligible for a
25 grant under subsection (a), an entity shall submit an ap-
26 plication to the Secretary at such time and in such manner

1 as the Secretary may require. Such application shall in-
2 clude—

3 “(1) evidence that such entity carries out, or is
4 capable of coordinating with other entities to carry
5 out, the activities described in subsection (g); and

6 “(2) such other information as the Secretary
7 may require.

8 “(e) PRIORITY.—In awarding grants under sub-
9 section (a), the Secretary shall give priority to eligible enti-
10 ties located in a State with an overdose mortality rate that
11 is above the national overdose mortality rate, as deter-
12 mined by the Director of the Centers for Disease Control
13 and Prevention.

14 “(f) PREFERENCE.—In awarding grants under sub-
15 section (a), the Secretary may give preference to eligible
16 entities utilizing technology-enabled collaborative learning
17 and capacity building models, including such models as de-
18 fined in section 2 of the Expanding Capacity for Health
19 Outcomes Act (Public Law 114–270; 130 Stat. 1395), to
20 conduct the activities described in this section.

21 “(g) CENTER ACTIVITIES.—Each Center shall, at a
22 minimum, carry out the following activities directly,
23 through referral, or through contractual arrangements,
24 which may include carrying out such activities through

1 technology-enabled collaborative learning and capacity
2 building models described in subsection (f):

3 “(1) TREATMENT AND RECOVERY SERVICES.—

4 Each Center shall—

5 “(A) ensure that intake and evaluations
6 meet the individualized clinical needs of pa-
7 tients, including by offering assessments for
8 services and care recommendations through
9 independent, evidence-based verification proc-
10 esses for reviewing patient placement in treat-
11 ment settings;

12 “(B) provide the full continuum of treat-
13 ment services, including—

14 “(i) all drugs approved by the Food
15 and Drug Administration to treat sub-
16 stance use disorders;

17 “(ii) medically supervised withdrawal
18 management that includes patient evalua-
19 tion, stabilization, and readiness for and
20 entry into treatment;

21 “(iii) counseling provided by a pro-
22 gram counselor or other certified profes-
23 sional who is licensed and qualified by edu-
24 cation, training, or experience to assess the
25 psychological and sociological background

1 of patients, to contribute to the appro-
2 priate treatment plan for the patient, and
3 to monitor patient progress;

4 “(iv) treatment, as appropriate, for
5 patients with co-occurring substance use
6 and mental health disorders;

7 “(v) residential rehabilitation, and
8 outpatient and intensive outpatient pro-
9 grams;

10 “(vi) recovery housing;

11 “(vii) community-based and peer re-
12 covery support services;

13 “(viii) job training, job placement as-
14 sistance, and continuing education assist-
15 ance to support reintegration into the
16 workforce; and

17 “(ix) other best practices to provide
18 the full continuum of treatment and serv-
19 ices, as determined by the Secretary;

20 “(C) periodically conduct patient assess-
21 ments to support sustained and clinically sig-
22 nificant recovery, as defined by the Assistant
23 Secretary for Mental Health and Substance
24 Use;

1 “(D) administer an onsite pharmacy and
2 provide toxicology services, for purposes of car-
3 rying out this section; and

4 “(E) operate a secure, confidential, and
5 interoperable electronic health information sys-
6 tem.

7 “(2) OUTREACH.—Each Center shall carry out
8 outreach activities to publicize the services offered
9 through the Centers, which may include—

10 “(A) training and supervising outreach
11 staff, as appropriate, to work with State and
12 local health departments, health care providers,
13 State and local education agencies, institutions
14 of higher education, State and local workforce
15 development boards, State and local community
16 action agencies, public safety officials, first re-
17 sponders, child welfare agencies, as appropriate,
18 and other community partners and the public,
19 including patients, to identify and respond to
20 community needs, and ensuring that such enti-
21 ties are aware of the services of the Center; and

22 “(B) disseminating and making publicly
23 available, including through the internet, evi-
24 dence-based resources that educate profes-
25 sionals and the public on opioid use disorder

1 and other substance use disorders, including co-
2 occurring substance use and mental health dis-
3 orders.

4 “(h) DATA REPORTING AND PROGRAM OVER-
5 SIGHT.—With respect to a grant awarded under sub-
6 section (a), not later than 90 days after the end of the
7 first year of the grant period, and annually thereafter for
8 the duration of the grant period (including the duration
9 of any renewal period for such grant), the entity shall sub-
10 mit data, as appropriate, to the Secretary regarding—

11 “(1) the programs and activities funded by the
12 grant;

13 “(2) health outcomes of the population of indi-
14 viduals with a substance use disorder who received
15 services from the Center, evaluated by an inde-
16 pendent program evaluator through the use of out-
17 comes measures, as determined by the Secretary;

18 “(3) the retention rate of program participants;
19 and

20 “(4) any other information that the Secretary
21 may require for the purpose of ensuring that the
22 Center is complying with all the requirements of the
23 grant, including providing the full continuum of
24 services described in subsection (g)(1)(B).

1 “(i) PRIVACY.—The provisions of this section, includ-
 2 ing with respect to data reporting and program oversight,
 3 shall be subject to all applicable Federal and State privacy
 4 laws.

5 “(j) AUTHORIZATION OF APPROPRIATIONS.—There
 6 is authorized to be appropriated \$10,000,000 for each of
 7 fiscal years 2019 through 2023 for purposes of carrying
 8 out this section.”.

9 (b) REPORTS TO CONGRESS.—

10 (1) PRELIMINARY REPORT.—Not later than 3
 11 years after the date of the enactment of this Act, the
 12 Secretary of Health and Human Services shall sub-
 13 mit to Congress a preliminary report that analyzes
 14 data submitted under section 550(h) of the Public
 15 Health Service Act, as added by subsection (a).

16 (2) FINAL REPORT.—Not later than 2 years
 17 after submitting the preliminary report required
 18 under paragraph (1), the Secretary of Health and
 19 Human Services shall submit to Congress a final re-
 20 port that includes—

21 (A) an evaluation of the effectiveness of
 22 the comprehensive services provided by the Cen-
 23 ters established or operated pursuant to section
 24 550 of the Public Health Service Act, as added
 25 by subsection (a), on health outcomes of the

population of individuals with substance use disorder who receive services from the Center, which shall include an evaluation of the effectiveness of services for treatment and recovery support and to reduce relapse, recidivism, and overdose; and

(B) recommendations, as appropriate, regarding ways to improve Federal programs related to substance use disorders, which may include dissemination of best practices for the treatment of substance use disorders to health care professionals.

SEC. 402. PROGRAM TO SUPPORT COORDINATION AND CONTINUATION OF CARE FOR DRUG OVERDOSE PATIENTS.

(a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall identify or facilitate the development of best practices for—

(1) emergency treatment of known or suspected drug overdose;

(2) coordination and continuation of care and treatment, including, as appropriate, through referrals, of individuals after an opioid overdose; and

1 (3) the provision of overdose reversal medica-
2 tion, as appropriate.

3 (b) GRANT ESTABLISHMENT AND PARTICIPATION.—

4 (1) IN GENERAL.—The Secretary shall award
5 grants on a competitive basis to eligible entities to
6 support implementation of voluntary programs for
7 care and treatment of individuals after an opioid
8 overdose, as appropriate, which may include imple-
9 mentation of the best practices described in sub-
10 section (a).

11 (2) ELIGIBLE ENTITY.—In this section, the
12 term “eligible entity” means an entity that offers
13 treatment or other services for individuals in re-
14 sponse to, or following, drug overdoses or a drug
15 overdose.

16 (3) APPLICATION.—An eligible entity desiring a
17 grant under this section, in consultation with the
18 principal agency of a State in which such entity of-
19 fers treatment or other services that is responsible
20 for carrying out the block grant for prevention and
21 treatment of substance abuse under subpart II of
22 part B of title XIX of the Public Health Service Act
23 (42 U.S.C. 300x–21 et seq.), shall submit an appli-
24 cation to the Secretary, at such time and in such

1 manner as the Secretary may require, that in-
2 cludes—

3 (A) evidence that such eligible entity car-
4 ries out, or is capable of coordinating with
5 other entities to carry out, the activities de-
6 scribed in paragraph (4); and

7 (B) such additional information as the Sec-
8 retary may require.

9 (4) USE OF GRANT FUNDS.—An eligible entity
10 awarded a grant under this section shall use such
11 grant funds to—

12 (A) hire or utilize recovery coaches to help
13 support recovery, including by—

14 (i) connecting patients to a continuum
15 of care services, such as—

16 (I) treatment and recovery sup-
17 port programs;

18 (II) programs that provide non-
19 clinical recovery support services;

20 (III) peer support networks;

21 (IV) recovery community organi-
22 zations;

23 (V) health care providers, includ-
24 ing physicians and other providers of
25 behavioral health and primary care;

1 (VI) educational and vocational
2 schools;

3 (VII) employers;

4 (VIII) housing services; and

5 (IX) child welfare agencies;

6 (ii) providing education on overdose
7 prevention to patients; and

8 (iii) providing other services the Sec-
9 retary determines necessary to help ensure
10 continued connection with recovery support
11 services;

12 (B) establish policies and procedures that
13 address the provision of overdose reversal medi-
14 cation, the administration of all drugs approved
15 by the Food and Drug Administration to treat
16 substance use disorder, and subsequent continu-
17 ation of, or referral to, evidence-based treat-
18 ment for patients with a substance use disorder
19 who have experienced a non-fatal drug over-
20 dose, in order to prevent relapse, and reduce re-
21 cidivism and future overdose;

22 (C) develop or implement best practices for
23 treating non-fatal drug overdoses, including,
24 with respect to care coordination and integrated
25 care models, for long term treatment and recov-

1 ery options for individuals with a substance use
2 disorder who have experienced a non-fatal drug
3 overdose; and

4 (D) establish integrated models of care for
5 individuals who have experienced a non-fatal
6 drug overdose which may include patient as-
7 sessment, follow up, and transportation to and
8 from treatment facilities.

9 (5) ADDITIONAL PERMISSIBLE USES.—In addi-
10 tion to the uses described in paragraph (4), a grant
11 awarded under this section may be used, directly or
12 through contractual arrangements, to provide—

13 (A) all drugs approved by the Food and
14 Drug Administration to treat substance use dis-
15 orders, pursuant to Federal and State law;

16 (B) withdrawal and detoxification services
17 that include patient evaluation, stabilization,
18 and preparation for treatment of substance use
19 disorder, including treatment described in sub-
20 paragraph (A), as appropriate; or

21 (C) mental health services provided by a
22 program counselor, social worker, therapist, or
23 other certified professional who is licensed and
24 qualified by education, training, or experience
25 to assess the psychosocial background of pa-

1 tients, to contribute to the appropriate treat-
2 ment plan for patients with substance use dis-
3 order, and to monitor patient progress.

4 (6) PREFERENCE.—In awarding grants under
5 this section, the Secretary shall give preference to el-
6 igible entities that meet any or all of the following
7 criteria:

8 (A) The eligible entity is a critical access
9 hospital (as defined in section 1861(mm)(1) of
10 the Social Security Act (42 U.S.C.
11 1395x(mm)(1))), a low volume hospital (as de-
12 fined in section 1886(d)(12)(C)(i) of such Act
13 (42 U.S.C. 1395ww(d)(12)(C)(i))), or a sole
14 community hospital (as defined in section
15 1886(d)(5)(D)(iii) of such Act (42 U.S.C.
16 1395ww(d)(5)(D)(iii))).

17 (B) The eligible entity is located in a State
18 with an overdose mortality rate that is above
19 the national overdose mortality rate, as deter-
20 mined by the Director of the Centers for Dis-
21 ease Control and Prevention.

22 (C) The eligible entity demonstrates that
23 recovery coaches will be placed in both health
24 care settings and community settings.

1 (7) PERIOD OF GRANT.—A grant awarded to an
 2 eligible entity under this section shall be for a period
 3 of not more than 5 years.

4 (c) DEFINITION.—In this section, the term “recovery
 5 coach” means an individual—

6 (1) with knowledge of, or experience with, re-
 7 covery from a substance use disorder; and

8 (2) who has completed training from, and is de-
 9 termined to be in good standing by, a recovery serv-
 10 ices organization capable of conducting such training
 11 and making such determination.

12 (d) REPORTING REQUIREMENTS.—

13 (1) REPORTS BY GRANTEEES.—Each eligible en-
 14 tity awarded a grant under this section shall submit
 15 to the Secretary an annual report for each year for
 16 which the entity has received such grant that in-
 17 cludes information on—

18 (A) the number of individuals treated by
 19 the entity for non-fatal overdoses, including the
 20 number of non-fatal overdoses where overdose
 21 reversal medication was administered;

22 (B) the number of individuals administered
 23 medication-assisted treatment by the entity;

24 (C) the number of individuals referred by
 25 the entity to other treatment facilities after a

1 non-fatal overdose, the types of such other fa-
2 cilities, and the number of such individuals ad-
3 mitted to such other facilities pursuant to such
4 referrals; and

5 (D) the frequency and number of patients
6 with reoccurrences, including readmissions for
7 non-fatal overdoses and evidence of relapse re-
8 lated to substance abuse disorder.

9 (2) REPORT BY SECRETARY.—Not later than 5
10 years after the date of enactment of this Act, the
11 Secretary shall submit to Congress a report that in-
12 cludes an evaluation of the effectiveness of the grant
13 program carried out under this section with respect
14 to long term health outcomes of the population of in-
15 dividuals who have experienced a drug overdose, the
16 percentage of patients treated or referred to treat-
17 ment by grantees, and the frequency and number of
18 patients who experienced relapse, were readmitted
19 for treatment, or experienced another overdose.

20 (e) PRIVACY.—The requirements of this section, in-
21 cluding with respect to data reporting and program over-
22 sight, shall be subject to all applicable Federal and State
23 privacy laws.

24 (f) AUTHORIZATION OF APPROPRIATIONS.—There is
25 authorized to be appropriated to carry out this section

1 such sums as may be necessary for each of fiscal years
2 2019 through 2023.

3 **SEC. 403. ALTERNATIVES TO OPIOIDS.**

4 (a) IN GENERAL.—The Secretary of Health and
5 Human Services shall, directly or through grants to, or
6 contracts with, public and private entities, provide tech-
7 nical assistance to hospitals and other acute care settings
8 on alternatives to opioids for pain management. The tech-
9 nical assistance provided shall be for the purpose of—

10 (1) utilizing information from acute care pro-
11 viders including emergency departments and other
12 providers that have successfully implemented alter-
13 natives to opioids programs, promoting non-opioid
14 protocols and medications while appropriately lim-
15 iting the use of opioids;

16 (2) identifying or facilitating the development of
17 best practices on the use of alternatives to opioids,
18 which may include pain-management strategies that
19 involve non-addictive medical products, non-pharma-
20 cologic treatments, and technologies or techniques to
21 identify patients at-risk for opioid use disorder;

22 (3) identifying or facilitating the development of
23 best practices on the use of alternatives to opioids
24 that target common painful conditions and include

1 certain patient populations, such as geriatric pa-
 2 tients, pregnant women, and children;

3 (4) disseminating information on the use of al-
 4 ternatives to opioids to providers in acute care set-
 5 tings, which may include emergency departments,
 6 outpatient clinics, critical access hospitals, and Fed-
 7 erally qualified health centers; and

8 (5) collecting data and reporting on health out-
 9 comes associated with the use of alternatives to
 10 opioids.

11 (b) AUTHORIZATION OF APPROPRIATIONS.—There is
 12 authorized to be appropriated to carry out this section
 13 such sums as may be necessary for each of fiscal years
 14 2019 through 2023.

15 **SEC. 404. PEER SUPPORT TECHNICAL ASSISTANCE.**

16 (a) TECHNICAL ASSISTANCE FOR PEER SUPPORT
 17 SERVICES.—The Secretary of Health and Human Services
 18 (referred to in this section as the “Secretary”), acting
 19 through the Assistant Secretary for Mental Health and
 20 Substance Abuse, shall provide technical assistance and
 21 support to organizations providing peer support services
 22 related to substance use disorder, including technical as-
 23 sistance and support related to—

24 (1) training on identifying—

25 (A) signs of substance use disorder;

1 (B) resources to assist individuals with a
 2 substance use disorder, or resources for families
 3 of an individual with a substance use disorder;
 4 and

5 (C) best practices for the delivery of recov-
 6 ery support services;

7 (2) the provision of translation services, inter-
 8 pretation, or other such services for clients with lim-
 9 ited English speaking proficiency;

10 (3) capacity building; and

11 (4) evaluation and improvement, as necessary,
 12 of the effectiveness of such peer support services.

13 (b) BEST PRACTICES.—The Secretary shall periodi-
 14 cally issue best practices related to peer support services
 15 for use by organizations that provide peer support serv-
 16 ices.

17 (c) AUTHORIZATION OF APPROPRIATIONS.—There is
 18 authorized to be appropriated to carry out this section
 19 such sums as may be necessary for each of fiscal years
 20 2019 through 2023.

21 **SEC. 405. MEDICATION-ASSISTED TREATMENT FOR RECOV-**
 22 **ERY FROM ADDICTION.**

23 (a) REPEAL OF REQUIREMENT TO UPDATE REGULA-
 24 TIONS.—Section 303 of the Comprehensive Addiction and

1 Recovery Act of 2016 (Public Law 114–198; 130 Stat.
2 720) is amended by striking subsection (c).

3 (b) CODIFICATION OF EXPANSION OF MAXIMUM
4 NUMBER OF PATIENTS FOR MEDICATION-ASSISTED
5 TREATMENT.—Section 303(g)(2)(B)(iii)(II) of the Con-
6 trolled Substances Act (21 U.S.C. (g)(2)(B)(iii)(II)) is
7 amended by striking “100” each place it appears and in-
8 serting “275”.

9 **SEC. 406. NATIONAL RECOVERY HOUSING BEST PRAC-**
10 **TICES.**

11 (a) BEST PRACTICES.—The Secretary of Health and
12 Human Services (referred to in this section as the “Sec-
13 retary”), in consultation with the Secretary for Housing
14 and Urban Development, patients with a history of opioid
15 use disorder, and other stakeholders, which may include
16 State accrediting entities and reputable providers of, and
17 analysts of, recovery housing services, shall identify or fa-
18 cilitate the development of best practices, which may in-
19 clude model laws for implementing suggested minimum
20 standards, for operating recovery housing.

21 (b) DISSEMINATION.—The Secretary shall dissemi-
22 nate the best practices identified or developed under sub-
23 section (a) to—

1 (1) State agencies, which may include the provi-
 2 sion of technical assistance to State agencies seeking
 3 to adopt or implement such best practices;

4 (2) recovery housing entities; and

5 (3) the public, as appropriate.

6 (c) REQUIREMENTS.—In identifying or facilitating
 7 the development of best practices under subsection (a), the
 8 Secretary, in consultation with appropriate stakeholders,
 9 shall consider how recovery housing is able to (including
 10 by improving access and adherence to treatment) support
 11 recovery and prevent relapse, recidivism, or overdose, in-
 12 cluding overdose death.

13 (d) RULE OF CONSTRUCTION.—Nothing in this sec-
 14 tion shall be construed to provide the Secretary with the
 15 ability to require States to adhere to minimum standards
 16 in the State oversight of recovery housing.

17 (e) DEFINITION.—In this section, the term “recovery
 18 housing” means a shared living environment free from al-
 19 cohol and illicit drug use and centered on peer support
 20 and connection to services that promote sustained recovery
 21 from substance use disorders.

22 **SEC. 407. ADDRESSING ECONOMIC AND WORKFORCE IM-**
 23 **PACTS OF THE OPIOID CRISIS.**

24 (a) DEFINITIONS.—Except as otherwise expressly
 25 provided, in this section:

1 (1) EDUCATION PROVIDER.—The term “edu-
2 cation provider” means—

3 (A) an institution of higher education, as
4 defined in section 101 of the Higher Education
5 Act of 1965 (20 U.S.C. 1001); or

6 (B) a postsecondary vocational institution,
7 as defined in section 102(c) of such Act (20
8 U.S.C. 1002(c)).

9 (2) ELIGIBLE ENTITY.—The term “eligible enti-
10 ty” means—

11 (A) a State workforce agency;

12 (B) a State board;

13 (C) an outlying area, as defined in section
14 3 of the Workforce Innovation and Opportunity
15 Act (29 U.S.C. 3102); or

16 (D) a Tribal entity.

17 (3) LOCAL AREA; LOCAL BOARD; ONE-STOP OP-
18 ERATOR.—The terms “local area”, “local board”,
19 and “one-stop operator” have the meanings given
20 such terms in section 3 of the Workforce Innovation
21 and Opportunity Act (29 U.S.C. 3102).

22 (4) LOCAL ENTITY.—The term “local entity”
23 means a local board or one-stop operator.

24 (5) PARTICIPATING PARTNERSHIP.—The term
25 “participating partnership” means a partnership es-

1 tablished under subsection (e)(1) by a local entity
2 receiving a subgrant under subsection (d).

3 (6) PROGRAM PARTICIPANT.—The term “pro-
4 gram participant” means an individual who—

5 (A) is a member of a population of workers
6 described in subsection (e)(2) that is served by
7 a participating partnership through the pilot
8 program under this section; and

9 (B) enrolls with the applicable partici-
10 pating partnership to receive any of the services
11 described in subsection (e)(3).

12 (7) SECRETARY.—The term “Secretary” means
13 the Secretary of Labor.

14 (8) STATE BOARD.—The term “State board”
15 has the meaning given the term in section 3 of the
16 Workforce Innovation and Opportunity Act (29
17 U.S.C. 3102).

18 (9) STATE WORKFORCE AGENCY.—The term
19 “State workforce agency” means the lead State
20 agency with responsibility for the administration of
21 a program under chapter 2 or 3 of subtitle B of title
22 I of the Workforce Innovation and Opportunity Act
23 (29 U.S.C. 3161 et seq., 3171 et seq.).

24 (10) SUBSTANCE USE DISORDER.—The term
25 “substance use disorder” means such a disorder

1 within the meaning of title V of the Public Health
 2 Service Act (42 U.S.C. 290aa et seq.).

3 (11) SUPPORTIVE SERVICES.—The term “sup-
 4 portive services” has the meaning given such term in
 5 section 3 of the Workforce Innovation and Oppor-
 6 tunity Act (29 U.S.C. 3102).

7 (12) TREATMENT PROVIDER.—The term “treat-
 8 ment provider”—

9 (A) means a health care provider that of-
 10 fers services for treating substance use dis-
 11 orders and is licensed in accordance with appli-
 12 cable State law to provide such services;

13 (B) accepts health insurance for such serv-
 14 ices, including coverage under title XIX of the
 15 Social Security Act (42 U.S.C. 1396 et seq.);
 16 and

17 (C) may include—

18 (i) a nonprofit provider of peer recov-
 19 ery support services, as defined by the
 20 State involved in regulation or guidance;

21 (ii) a community health care provider;

22 or

23 (iii) a Federally qualified health cen-
 24 ter (as defined in section 1861(aa) of the
 25 Social Security Act (42 U.S.C. 1395x)).

1 (13) TRIBAL ENTITY.—The term “Tribal enti-
2 ty” includes any Indian tribe, tribal organization,
3 Indian-controlled organization serving Indians, Na-
4 tive Hawaiian organization, or Alaska Native entity,
5 as such terms are defined or used in section 166 of
6 the Workforce Innovation and Opportunity Act (29
7 U.S.C. 3221).

8 (b) PILOT PROGRAM AND GRANTS AUTHORIZED.—

9 (1) IN GENERAL.—The Secretary, in consulta-
10 tion with the Secretary of Health and Human Serv-
11 ices, shall carry out a pilot program to address eco-
12 nomic and workforce impacts associated with a high
13 rate of a substance use disorder. In carrying out the
14 pilot program, the Secretary shall make grants, on
15 a competitive basis, to eligible entities to enable such
16 entities to make subgrants to local boards and one-
17 stop operators to address the economic and work-
18 force impacts associated with a high rate of a sub-
19 stance use disorder.

20 (2) GRANT AMOUNTS.—The Secretary shall
21 make each such grant in an amount that is not less
22 than \$500,000, and not more than \$5,000,000, for
23 a fiscal year.

24 (c) GRANT APPLICATIONS.—

1 (1) IN GENERAL.—An eligible entity applying
 2 for a grant under this section shall submit an appli-
 3 cation to the Secretary at such time and in such
 4 form and manner as the Secretary may reasonably
 5 require, including the information described in this
 6 subsection.

7 (2) SIGNIFICANT IMPACT ON COMMUNITY BY
 8 OPIOID ABUSE AND SUBSTANCE USE DISORDER-RE-
 9 LATED PROBLEMS.—

10 (A) DEMONSTRATION.—An eligible entity
 11 shall include in the application information that
 12 demonstrates significant impact on the commu-
 13 nity by problems related to opioid abuse or an-
 14 other substance use disorder, by—

15 (i) identifying the communities, re-
 16 gions, or local areas that will be served
 17 through the grant (each referred to in this
 18 section as a “service area”); and

19 (ii) showing, for each such service
 20 area, an increase equal to or greater than
 21 the national increase in such problems, be-
 22 tween—

23 (I) 1999; and

24 (II) 2016 or the latest year for
 25 which data are available.

1 (B) INFORMATION.—In making the show-
2 ing described in subparagraph (A)(ii), the eligi-
3 ble entity may use information including data
4 on—

5 (i) the incidence or prevalence of
6 opioid abuse and other substance use dis-
7 orders;

8 (ii) the per capita drug overdose mor-
9 tality rate, as determined by the Director
10 of the Centers for Disease Control and
11 Prevention;

12 (iii) the rate of non-fatal hospitaliza-
13 tions related to opioid abuse or another
14 substance use disorder; or

15 (iv) the number of arrests or convic-
16 tions, or a relevant law enforcement sta-
17 tistic, that reasonably shows an increase in
18 opioid abuse or another substance use dis-
19 order.

20 (C) SUPPORT FOR STATE STRATEGY.—The
21 eligible entity shall also include in the applica-
22 tion information describing how the proposed
23 services and activities support the State's strat-
24 egy for addressing problems described in sub-

paragraph (A) in specific regions or across the State, outlying area, or Tribal entity.

(3) ECONOMIC AND EMPLOYMENT CONDITIONS
DEMONSTRATE ADDITIONAL FEDERAL SUPPORT
NEEDED.—

(A) DEMONSTRATION.—An eligible entity shall include in the application information that demonstrates that a high rate of a substance use disorder has caused, or is coincident to, an economic or employment downturn in the service area.

(B) INFORMATION.—In making the demonstration described in subparagraph (A), the eligible entity may use information including—

(i) documentation of any layoff, announced future layoff, legacy industry decline, decrease in an employment or labor market participation rate, or economic impact, whether or not the result described in this clause is overtly related to a high rate of a substance use disorder;

(ii) documentation showing decreased economic activity related to, caused by, or contributing to a high rate of a substance use disorder, including a description of

1 how the service area has been impacted, or
2 will be impacted, by such a decrease;

3 (iii) in particular, information on eco-
4 nomic indicators, labor market analyses,
5 information from public announcements,
6 and demographic and industry data;

7 (iv) information on rapid response ac-
8 tivities (as defined in section 3 of the
9 Workforce Innovation and Opportunity Act
10 (29 U.S.C. 3102)) that have been or will
11 be conducted, including demographic data
12 gathered by employer or worker surveys or
13 through other methods;

14 (v) data or documentation, beyond an-
15 ecdotal evidence, showing that employers
16 face challenges filling job vacancies due to
17 a lack of skilled workers able to pass a
18 drug test; or

19 (vi) any additional relevant data or in-
20 formation on the economy, workforce, or
21 another aspect of the service area to sup-
22 port the application.

23 (4) WORKFORCE SHORTAGE RELATED TO
24 TREATMENT WORKFORCE.—

1 (A) IN GENERAL.—An eligible entity may
2 include in the application a demonstration of
3 the workforce shortage in a professional area to
4 be addressed under the grant. Such professional
5 areas may include—

6 (i) substance use disorder treatment
7 and related services;

8 (ii) non-opioid pain therapy and pain
9 management services; or

10 (iii) mental health care treatment
11 services.

12 (B) INFORMATION TO BE INCLUDED.—An
13 eligible entity demonstrating a workforce short-
14 age under subparagraph (A) shall demonstrate
15 the workforce shortage through information
16 that may include—

17 (i) the distance between—

18 (I) communities affected by
19 opioid abuse or another substance use
20 disorder; and

21 (II) facilities or professionals of-
22 fering services in the professional
23 area;

24 (ii) the maximum capacity of facilities
25 or professionals to serve individuals in an

1 affected community, or increases in arrests
 2 related to opioid abuse or another sub-
 3 stance use disorder, overdose deaths, or
 4 nonfatal overdose emergencies in the com-
 5 munity; or

6 (iii) other information that can dem-
 7 onstrate such a shortage.

8 (d) SUBGRANT AUTHORIZATION AND APPLICATION
 9 PROCESS.—

10 (1) SUBGRANTS AUTHORIZED.—

11 (A) IN GENERAL.—An eligible entity re-
 12 ceiving a grant under subsection (b)—

13 (i) may use not more than 5 percent
 14 of the grant funds for the administrative
 15 costs of carrying out the grant; and

16 (ii) shall use the remaining grant
 17 funds to make subgrants to local entities
 18 in the area served by the eligible entity to
 19 carry out the services and activities de-
 20 scribed in subsection (e).

21 (B) GEOGRAPHIC DISTRIBUTION.—In mak-
 22 ing subgrants under this subsection, an eligible
 23 entity shall ensure, to the extent practicable,
 24 the equitable geographic distribution (such as

1 urban and rural distribution) of areas receiving
2 subgrant funds.

3 (2) SUBGRANT APPLICATION.—

4 (A) IN GENERAL.—A local entity desiring
5 to receive a subgrant under this subsection shall
6 submit an application at such time and in such
7 and manner as the eligible entity may reason-
8 ably require, including the information de-
9 scribed in this paragraph.

10 (B) CONTENTS.—Each application de-
11 scribed in subparagraph (A) shall include an
12 analysis of the estimated performance of the
13 local entity in carrying out the proposed serv-
14 ices and activities under the subgrant that—

15 (i) uses primary indicators of per-
16 formance described in section
17 116(c)(1)(A)(i) of the Workforce Innova-
18 tion and Opportunity Act (29 U.S.C.
19 3141(c)(1)(A)(i)), to assess estimated ef-
20 fectiveness of the proposed services and ac-
21 tivities, including the estimated number of
22 individuals with a substance use disorder
23 who may be served by the proposed serv-
24 ices and activities;

1 (ii) analyzes the record of the local
2 entity in serving individuals with a barrier
3 to employment; and

4 (iii) analyzes the ability of the local
5 entity to establish the partnership de-
6 scribed in subsection (e)(1).

7 (C) ANALYSIS.—The analysis described in
8 subparagraph (B) may include or utilize—

9 (i) data from the National Center for
10 Health Statistics of the Centers for Dis-
11 ease Control and Prevention;

12 (ii) data from the Center for Behav-
13 ioral Health Statistics and Quality of the
14 Substance Abuse and Mental Health Serv-
15 ices Administration;

16 (iii) State vital statistics;

17 (iv) municipal police department
18 records;

19 (v) reports from local coroners; or

20 (vi) other relevant data.

21 (e) SUBGRANT SERVICES AND ACTIVITIES.—

22 (1) FORMATION OF PARTNERSHIP.—

23 (A) IN GENERAL.—Each local entity that
24 receives a subgrant under subsection (d) shall
25 form a partnership, established through a writ-

ten contract or other agreement, with members described in subparagraph (B), and shall carry out the services and activities described in this subsection through the partnership.

(B) MEMBERS OF THE PARTNERSHIP.—A partnership described in subparagraph (A) shall include 1 or more of the following:

- (i) The eligible entity.
- (ii) A treatment provider.
- (iii) An employer or industry organization.
- (iv) An education provider.
- (v) A justice or law enforcement organization.
- (vi) A faith-based or community-based organization.
- (vii) Other State or local agencies.
- (viii) Other organizations, as determined to be necessary by the local entity.

(2) SELECTION OF POPULATION TO BE SERVED.—A participating partnership shall elect to provide services and activities under the subgrant to one or both of the following populations of workers:

- (A) Workers, including dislocated workers, new entrants in the workforce, or incumbent

workers (employed or underemployed), who are directly or indirectly affected by a high rate of a substance use disorder and each of whom is—

(i) an individual who voluntarily confirms that the individual, or a friend or family member of the individual, has a history of opioid abuse or another substance use disorder; or

(ii) an individual who works or resides in a community substantially impacted by a high rate of a substance use disorder or can otherwise demonstrate job loss as a result of a high rate of a substance use disorder.

(B) Workers, including dislocated workers, new entrants in the workforce, or incumbent workers (employed or underemployed), who—

(i) seek to transition to professions that support individuals struggling with a substance use disorder or at risk for developing such disorder, such as professions that provide—

(I) substance use disorder treatment and related services;

1 (II) peer recovery support serv-
2 ices described in subsection
3 (a)(12)(C)(i);

4 (III) non-opioid pain therapy and
5 pain management services; or

6 (IV) mental health care; and

7 (ii) need new or upgraded skills to
8 better serve such a population of strug-
9 gling or at-risk individuals.

10 (3) SERVICES AND ACTIVITIES.—Each partici-
11 pating partnership shall use funds available through
12 a subgrant under this subsection to carry out 1 or
13 more of the following:

14 (A) ENGAGING EMPLOYERS.—Engaging
15 with employers to—

16 (i) learn about the skill and hiring re-
17 quirements of employers;

18 (ii) learn about the support needed by
19 employers to hire and retain program par-
20 ticipants, and other individuals with a sub-
21 stance use disorder, and the support need-
22 ed by such employers to obtain their com-
23 mitment to testing creative solutions to
24 employing program participants and such
25 individuals;

1 (iii) connect employers and workers to
2 on-the-job or customized training programs
3 before or after layoff to help facilitate re-
4 employment;

5 (iv) connect employers with an edu-
6 cation provider to develop classroom in-
7 struction to complement on-the-job learn-
8 ing for program participants and such in-
9 dividuals;

10 (v) help employers develop the cur-
11 riculum design of a work-based learning
12 program for program participants and
13 such individuals; or

14 (vi) help employers employ program
15 participants or such individuals engaging
16 in a work-based learning program for a
17 transitional period before hiring such a
18 program participant or individual for full-
19 time employment of not less than 30 hours
20 a week.

21 (B) SCREENING SERVICES.—Providing
22 screening services, which may include—

23 (i) using an evidence-based screening
24 method to screen each individual seeking
25 participation in the pilot program to deter-

mine whether the individual has a substance use disorder;

(ii) conducting an assessment of each such individual to determine the services needed for such individual to obtain or retain employment, including an assessment of strengths and general work readiness; and

(iii) accepting walk-ins or referrals from employers, labor organizations, or other entities recommending individuals to participate in such program.

(C) INDIVIDUAL TREATMENT AND EMPLOYMENT PLAN.—Developing an individual treatment and employment plan for each program participant, which shall include providing a case manager to work with each participant to develop the plan, which may include—

(i) identifying employment and career goals;

(ii) exploring career pathways that lead to in-demand industries and sectors as determined by the State board and the head of the State workforce agency;

- 1 (iii) setting appropriate achievement
- 2 objectives to attain the employment and
- 3 career goals identified under clause (i); or
- 4 (iv) developing the appropriate com-
- 5 bination of services to enable the partici-
- 6 pant to achieve the employment and career
- 7 goals.

8 (D) OUTPATIENT TREATMENT AND RECOV-
 9 ERY CARE.—In the case of a participating part-
 10 nership serving program participants described
 11 in paragraph (2)(A)(i) with a substance use dis-
 12 order, providing individualized and group out-
 13 patient treatment and recovery services for such
 14 program participants that are offered during
 15 the day and evening, and on weekends. Such
 16 treatment and recovery services—

- 17 (i) shall be based on a model that uti-
- 18 lizes combined behavioral interventions and
- 19 other evidence-based or evidence-informed
- 20 interventions; and

- 21 (ii) may include additional services
- 22 such as—

- 23 (I) health, mental health, addic-
- 24 tion, or other forms of outpatient
- 25 treatment that may impact a sub-

stance use disorder and co-occurring conditions;

(II) drug testing for a current substance use disorder prior to enrollment in career or training services or prior to employment;

(III) linkages to community services, including services offered by partner organizations designed to support program participants; and

(IV) referrals to health care, including referrals to substance use disorder treatment and mental health services.

(E) SUPPORTIVE SERVICES.—Providing supportive services, which shall include services such as—

(i) coordinated wraparound services to provide maximum support for program participants to ensure that the program participants maintain employment and recovery for not less than 12 months, as appropriate;

(ii) assistance in establishing eligibility for assistance under Federal, State,

1 and local programs providing health serv-
 2 ices, mental health services, housing serv-
 3 ices, transportation services, or social serv-
 4 ices;

5 (iii) peer recovery support services de-
 6 scribed in subsection (a)(12)(C)(i);

7 (iv) networking and mentorship op-
 8 portunities; or

9 (v) any supportive services determined
 10 necessary by the local entity.

11 (F) CAREER AND JOB TRAINING SERV-
 12 ICES.—Offering career services and training
 13 services, and related services, concurrently or
 14 sequentially with the services provided under
 15 subparagraphs (B) through (E). Such services
 16 shall include the following:

17 (i) Services provided to program par-
 18 ticipants who are in a pre-employment
 19 stage of the program. Such services may
 20 include—

21 (I) initial education and skills as-
 22 sessments;

23 (II) traditional classroom train-
 24 ing funded through individual training
 25 accounts under chapter 3 of subtitle B

1 of title I of the Workforce Innovation
2 and Opportunity Act (29 U.S.C. 3171
3 et seq.);

4 (III) services to promote employ-
5 ability skills such as punctuality, per-
6 sonal maintenance skills, and profes-
7 sional conduct;

8 (IV) in-depth interviewing and
9 evaluation to identify employment bar-
10 riers and to develop individual em-
11 ployment plans;

12 (V) career planning that in-
13 cludes—

14 (aa) career pathways leading
15 to in-demand, high-wage jobs;
16 and

17 (bb) job coaching, job
18 matching, and job placement
19 services;

20 (VI) provision of payments and
21 fees for employment and training-re-
22 lated applications, tests, and certifi-
23 cations; or

24 (VII) any other appropriate ca-
25 reer service or training service de-

1 scribed in section 134(c) of the Work-
2 force Innovation and Opportunity Act
3 (29 U.S.C. 3174(c)).

4 (ii) Services provided to program par-
5 ticipants during their first 6 months of
6 employment to ensure job retention, which
7 may include—

8 (I) case management and support
9 services, including a continuation of
10 the services described in clause (i);

11 (II) a continuation of skills train-
12 ing, and career and technical edu-
13 cation, described in clause (i) that is
14 conducted in collaboration with the
15 employers of such participants;

16 (III) mentorship services and job
17 retention support for such partici-
18 pants; or

19 (IV) targeted training for man-
20 agers and workers working with such
21 participants (such as mentors), and
22 human resource representatives in the
23 business in which such participants
24 are employed.

1 (iii) Services to assist program partici-
 2 pants in maintaining employment for not
 3 less than 12 months, as appropriate.

4 (G) PROVEN AND PROMISING PRAC-
 5 TICES.—Leading efforts in the service area to
 6 identify and promote proven and promising
 7 strategies and initiatives for meeting the needs
 8 of employers and program participants.

9 (4) LIMITATIONS.—A participating partnership
 10 may not use—

11 (A) more than 5 percent of the funds re-
 12 ceived under a subgrant under subsection (d)
 13 for the administrative costs of the partnership;

14 (B) more than 10 percent of the funds re-
 15 ceived under such subgrant for the provision of
 16 treatment and recovery services, as described in
 17 paragraph (3)(D); or

18 (C) more than 10 percent of the funds re-
 19 ceived under such subgrant for the provision of
 20 supportive services described in paragraph
 21 (3)(E) to program participants.

22 (f) PERFORMANCE ACCOUNTABILITY.—

23 (1) REPORTS.—The Secretary shall establish
 24 quarterly reporting requirements for recipients of
 25 grants and subgrants under this section that, to the

1 extent practicable, are based on the performance ac-
 2 countability system under section 116 of the Work-
 3 force Innovation and Opportunity Act (29 U.S.C.
 4 3141), including the indicators described in sub-
 5 section (c)(1)(A)(i) of such section and the require-
 6 ments for local area performance reports under sub-
 7 section (d) of such section.

8 (2) EVALUATIONS.—

9 (A) AUTHORITY TO ENTER INTO AGREE-
 10 MENTS.—The Secretary shall ensure that an
 11 independent evaluation is conducted on the pilot
 12 program carried out under this section to deter-
 13 mine the impact of the program on employment
 14 of individuals with substance use disorders. The
 15 Secretary shall enter into an agreement with el-
 16 igible entities receiving grants under this sec-
 17 tion to pay for all or part of such evaluation.

18 (B) METHODOLOGIES TO BE USED.—The
 19 independent evaluation required under this
 20 paragraph shall use experimental designs using
 21 random assignment or, when random assign-
 22 ment is not feasible, other reliable, evidence-
 23 based research methodologies that allow for the
 24 strongest possible causal inferences.

25 (g) FUNDING.—

1 (1) COVERED FISCAL YEAR.—In this sub-
 2 section, the term “covered fiscal year” means any of
 3 fiscal years 2018 through 2023.

4 (2) USING FUNDING FOR NATIONAL DIS-
 5 LOCATED WORKER GRANTS.—Subject to paragraph
 6 (4) and notwithstanding section 132(a)(2)(A) and
 7 subtitle D of the Workforce Innovation and Oppor-
 8 tunity Act (29 U.S.C. 3172(a)(2)(A), 3221 et seq.)
 9 or any other provision of law, the Secretary may use,
 10 to carry out the pilot program under this section for
 11 a covered fiscal year—

12 (A) funds made available to carry out sec-
 13 tion 170 of such Act (29 U.S.C. 3225) for that
 14 fiscal year;

15 (B) funds made available to carry out sec-
 16 tion 170 of such Act that remain available for
 17 that fiscal year; and

18 (C) funds that remain available under sec-
 19 tion 172(f) of such Act (29 U.S.C. 3227(f)).

20 (3) AVAILABILITY OF FUNDS.—Funds appro-
 21 priated under section 136(c) of such Act (29 U.S.C.
 22 3181(c)) and made available to carry out section
 23 170 of such Act for a fiscal year shall remain avail-
 24 able for use under paragraph (2) for a subsequent
 25 fiscal year until expended.

1 (4) LIMITATION.—The Secretary may not use
 2 more than \$100,000,000 of the funds described in
 3 paragraph (2) for any covered fiscal year under this
 4 section.

5 **SEC. 408. YOUTH PREVENTION AND RECOVERY.**

6 (a) SUBSTANCE ABUSE TREATMENT SERVICES FOR
 7 CHILDREN, ADOLESCENTS, AND YOUNG ADULTS.—Sec-
 8 tion 514 of the Public Health Service Act (42 U.S.C.
 9 290bb-7) is amended—

10 (1) in the section heading, by striking “**CHIL-**
 11 **DREN AND ADOLESCENTS**” and inserting “**CHIL-**
 12 **DREN, ADOLESCENTS, AND YOUNG ADULTS**”;

13 (2) in subsection (a)(2), by striking “children,
 14 including” and inserting “children, adolescents, and
 15 young adults, including”; and

16 (3) by striking “children and adolescents” each
 17 place it appears and inserting “children, adolescents,
 18 and young adults”.

19 (b) YOUTH PREVENTION AND RECOVERY INITIA-
 20 TIVE.—

21 (1) DEFINITIONS.—In this subsection:

22 (A) ELIGIBLE ENTITY.—The term “eligible
 23 entity” means—

24 (i) a local educational agency that is
 25 seeking to establish or expand substance

1 use prevention and recovery support serv-
 2 ices at one or more high schools;

3 (ii) an institution of higher education;

4 (iii) a recovery program at an institu-
 5 tion of higher education;

6 (iv) a local board or one-stop oper-
 7 ator; or

8 (v) a nonprofit organization, excluding
 9 a school.

10 (B) HIGH SCHOOL.—The term “high
 11 school” has the meaning given such term in
 12 section 8101 of the Elementary and Secondary
 13 Education Act of 1965 (20 U.S.C. 7801).

14 (C) INSTITUTION OF HIGHER EDU-
 15 CATION.—The term “institution of higher edu-
 16 cation” has the meaning given such term in
 17 section 101 of the Higher Education Act of
 18 1965 (20 U.S.C. 1001) and includes a “post-
 19 secondary vocational institution” as defined in
 20 section 102(c) of such Act (20 U.S.C. 1002(c)).

21 (D) LOCAL EDUCATION AGENCY.—The
 22 term “local educational agency” has the mean-
 23 ing given the term in section 8101 of the Ele-
 24 mentary and Secondary Education Act of 1965.

1 (E) LOCAL BOARD; ONE-STOP OPER-
2 ATOR.—The terms “local board” and “one-stop
3 operator” have the meanings given such terms
4 in section 3 of the Workforce Innovation and
5 Opportunity Act (29 U.S.C. 3102).

6 (F) RECOVERY PROGRAM.—The term “re-
7 covery program” means a program—

8 (i) to help children, adolescents, or
9 young adults who are recovering from sub-
10 stance use disorders to initiate, stabilize,
11 and maintain healthy and productive lives
12 in the community; and

13 (ii) that includes peer-to-peer support
14 delivered by individuals with lived experi-
15 ence in recovery, and communal activities
16 to build recovery skills and supportive so-
17 cial networks.

18 (G) SECRETARY.—The term “Secretary”
19 means the Secretary of Health and Human
20 Services, except as otherwise specified.

21 (2) BEST PRACTICES.—The Secretary, in con-
22 sultation with the Secretary of Education, shall—

23 (A) identify or facilitate the development of
24 evidence-based best practices for prevention of
25 substance misuse and abuse by children, adoles-

1 cents, and young adults, for appropriate recov-
2 ery support services, and for appropriate use of
3 medication-assisted treatment for such individ-
4 uals, if applicable;

5 (B) disseminate such best practices to local
6 educational agencies, institutions of higher edu-
7 cation, recovery programs at institutions of
8 higher education, local boards, one-stop opera-
9 tors, and nonprofit organizations, as appro-
10 priate;

11 (C) conduct a rigorous, independent eval-
12 uation of each grant funded under this sub-
13 section, particularly its impact on the indicators
14 described in paragraph (5)(B); and

15 (D) provide technical assistance for grant-
16 ees under this subsection.

17 (3) GRANTS AUTHORIZED.—The Secretary, in
18 consultation with the Secretary of Education, shall
19 award 3-year grants, on a competitive basis, to eligi-
20 ble entities to enable such entities, in coordination
21 with State agencies responsible for carrying out sub-
22 stance use disorder prevention and treatment pro-
23 grams, to carry out evidence-based or promising pro-
24 grams for—

1 (A) prevention of substance abuse and mis-
2 use by children, adolescents, and young adults;

3 (B) recovery support services for children,
4 adolescents, and young adults, which may in-
5 clude counseling, job training, linkages to com-
6 munity-based services, family support groups,
7 and recovery coaching; and

8 (C) treatment or referrals for treatment of
9 substance use disorders, as appropriate.

10 (4) APPLICATION.—To be eligible for a grant
11 under this subsection, an entity shall submit to the
12 Secretary an application at such time, in such man-
13 ner, and containing such information as the Sec-
14 retary may require. Such application shall include—

15 (A) a description of the impact of sub-
16 stance use disorders on children, adolescents,
17 and young adults enrolled in the local edu-
18 cational agency, one-stop operator, local board,
19 or institution of higher education;

20 (B) a description of how the eligible entity
21 has solicited input from faculty, teachers, staff,
22 families, students, and experts in substance use
23 prevention and treatment in developing such
24 application;

1 (C) how the eligible entity plans to use
2 grant funds for evidence-based or promising ac-
3 tivities, in accordance with this subsection to
4 prevent, provide recovery support for, and treat
5 substance use disorders amongst such individ-
6 uals;

7 (D) an assurance that the eligible entity
8 will participate in the evaluation described in
9 paragraph (2)(C); and

10 (E) a description of how the eligible entity
11 will collaborate with local service providers, in-
12 cluding substance use disorder treatment pro-
13 grams, providers of mental health services, and
14 primary care providers, in carrying out the
15 grant program.

16 (5) REPORT.—Each eligible entity awarded a
17 grant under this section shall submit to the appro-
18 priate committees of Congress, a report at such time
19 and in such manner as the Secretary may require.
20 Such report shall include—

21 (A) a description of how the eligible entity
22 used grant funds, in accordance with this sub-
23 section, including the number of children, ado-
24 lescents, and young adults reached through pro-
25 gramming; and

1 (B) a description of how the grant pro-
 2 gram has made an impact on—

3 (i) indicators of student success, in-
 4 cluding student well-being and academic
 5 achievement; and

6 (ii) substance use disorders amongst
 7 children, adolescents, and young adults, in-
 8 cluding the number of overdoses and
 9 deaths amongst children, adolescents, and
 10 young adults during the grant period.

11 (6) AUTHORIZATION OF APPROPRIATIONS.—

12 There is authorized to be appropriated, such sums
 13 as may be necessary to carry out this subsection.

14 **SEC. 409. PLANS OF SAFE CARE.**

15 (a) IN GENERAL.—Section 105(a) of the Child Abuse
 16 Prevention and Treatment Act (42 U.S.C. 5106(a)) is
 17 amended by adding at the end the following:

18 “(7) GRANTS TO STATES TO IMPROVE AND CO-
 19 ORDINATE THEIR RESPONSE TO ENSURE THE SAFE-
 20 TY, PERMANENCY, AND WELL-BEING OF INFANTS
 21 AFFECTED BY SUBSTANCE USE.—

22 “(A) PROGRAM AUTHORIZED.—The Sec-
 23 retary shall make grants to States for the pur-
 24 pose of assisting child welfare agencies, social
 25 services agencies, substance use disorder treat-

ment agencies, public health and mental health agencies, and maternal and child health agencies to facilitate collaboration in developing, updating, and implementing plans of safe care described in section 106(b)(2)(B)(iii).

“(B) DISTRIBUTION OF FUNDS.—

“(i) RESERVATIONS.—Of the amounts appropriated under subparagraph (H), the Secretary shall reserve—

“(I) no more than 3 percent for the purposes described in subparagraph (G); and

“(II) up to 3 percent for grants to Indian Tribes and tribal organizations for purposes consistent with this section, as the Secretary determines appropriate.

“(ii) ALLOTMENTS TO STATES AND TERRITORIES.—The Secretary shall allot the amount appropriated under subparagraph (H) that remains after application of clause (i) on a competitive basis to States that apply for such a grant.

“(iii) SELECTION CRITERIA.—The Secretary shall allot funds to States that

1 demonstrate a strong need for such funds,
2 and a strong commitment to using such
3 funds, to meet the purposes described in
4 subparagraph (A) in accordance with sub-
5 paragraph (D).

6 “(C) APPLICATION.—A State desiring a
7 grant under this paragraph shall submit an ap-
8 plication to the Secretary at such time and in
9 such manner as the Secretary may require.
10 Such application shall include—

11 “(i) a description of—

12 “(I) the impact of substance use
13 disorder in such State, including with
14 respect to the substance or class of
15 substances with the highest incidence
16 of abuse in the previous year in such
17 State, including—

18 “(aa) the prevalence of sub-
19 stance use disorder in such State;

20 “(bb) the aggregate rate of
21 births in the State of infants af-
22 fected by substance abuse or
23 withdrawal symptoms or a fetal
24 alcohol spectrum disorder (as de-
25 termined by hospitals, insurance

1 claims, claims submitted to the
2 State Medicaid program, or other
3 records), if available and to the
4 extent practicable; and

5 “(cc) the number of infants
6 identified, for whom a plan of
7 safe care was developed, and for
8 whom a referral was made for
9 appropriate services, as reported
10 under section 106(d)(18);

11 “(II) the challenges the State
12 faces in developing and implementing
13 plans of safe care in accordance with
14 section 106(b)(2)(B)(iii);

15 “(III) the State’s lead agency for
16 the grant program and how that agen-
17 cy will coordinate with relevant State
18 entities and programs, including the
19 child welfare agency, the substance
20 use disorder treatment agency, the
21 public health and mental health agen-
22 cies, programs funded by the Residen-
23 tial Treatment for Pregnant and
24 Postpartum Women grant program of
25 the Substance Abuse and Mental

1 Health Services Administration under
2 section 508 of the Public Health Serv-
3 ice Act (42 U.S.C. 290bb-1), the
4 State Medicaid program, the State
5 agency administering the block grant
6 program under title V of the Social
7 Security Act (42 U.S.C. 701 et seq.),
8 the State agency administering the
9 programs funded under part C of the
10 Individuals with Disabilities Edu-
11 cation Act (20 U.S.C. 1431 et seq.),
12 the maternal, infant, and early child-
13 hood home visiting program under
14 section 511 of the Social Security Act
15 (42 U.S.C. 711), the State judicial
16 system, and other agencies, as deter-
17 mined by the Secretary;

18 “(IV) how the State will monitor
19 local implementation of plans of safe
20 care, in accordance with section
21 106(b)(2)(B)(iii)(II);

22 “(V) how the State meets the re-
23 quirements of section 1927 of the
24 Public Health Service Act (42 U.S.C.
25 300x-27);

1 “(VI) how the State plans to uti-
2 lize funding authorized under part E
3 of title IV of the Social Security Act
4 (42 U.S.C. 670 et seq.) to assist in
5 carrying out any plan of safe care, in-
6 cluding such funding authorized under
7 section 471(e) of such Act (as in ef-
8 fect on October 1, 2018) for mental
9 health and substance abuse prevention
10 and treatment services and in-home
11 parent skill-based programs and fund-
12 ing authorized under such section
13 472(j) (as in effect on October 1,
14 2018) for children with a parent in a
15 licensed residential family-based treat-
16 ment facility for substance abuse; and
17 “(VII) an assessment of the
18 treatment and other services and pro-
19 grams available in the State, to effec-
20 tively carry out any plan of safe care
21 developed, including identification of
22 needed treatment, and other services
23 and programs to ensure the wellbeing
24 of young children and their families
25 affected by substance use disorder,

1 such as programs carried out under
2 part C of the Individuals with Disabil-
3 ities Education Act and comprehen-
4 sive early childhood development serv-
5 ices and programs such as Head Start
6 programs;

7 “(ii) a description of how the State
8 plans to use funds for activities described
9 in subparagraph (D) for the purposes of
10 ensuring State compliance with require-
11 ments under clauses (ii) and (iii) of section
12 106(b)(2)(B); and

13 “(iii) an assurance that the State
14 will—

15 “(I) comply with this Act and
16 parts B and E of title IV of the Social
17 Security Act (42 U.S.C. 621 et seq.,
18 670 et seq.); and

19 “(II) comply with requirements
20 to refer a child identified as sub-
21 stance-exposed to early intervention
22 services as required pursuant to a
23 grant under part C of the Individuals
24 with Disabilities Education Act (20
25 U.S.C. 1431 et seq.).

1 “(D) USES OF FUNDS.—Funds awarded to
 2 a State under this paragraph may be used for
 3 the following activities, which may be carried
 4 out by the State directly, or through grants or
 5 subgrants, contracts, or cooperative agreements:

6 “(i) Improving State and local sys-
 7 tems with respect to the development and
 8 implementation of plans of safe care,
 9 which—

10 “(I) shall include parent and
 11 caregiver engagement, as required
 12 under section 106(b)(2)(B)(iii)(I), re-
 13 garding available treatment and serv-
 14 ice options, which may include re-
 15 sources available for pregnant,
 16 perinatal, and postnatal women; and

17 “(II) may include activities such
 18 as—

19 “(aa) developing policies,
 20 procedures, or protocols for the
 21 administration of evidence-based
 22 and validated screening tools for
 23 infants who may be affected by
 24 substance use withdrawal symp-
 25 toms or a fetal alcohol spectrum

1 disorder and pregnant, perinatal,
2 and postnatal women whose in-
3 fants may be affected by sub-
4 stance use withdrawal symptoms
5 or a fetal alcohol spectrum dis-
6 order;

7 “(bb) improving assessments
8 used to determine the needs of
9 the infant and family;

10 “(cc) improving ongoing
11 case management services; and

12 “(dd) improving access to
13 treatment services, which may be
14 prior to the pregnant woman’s
15 delivery date.

16 “(ii) Developing policies, procedures,
17 or protocols in consultation and coordina-
18 tion with health professionals, public and
19 private health facilities, and substance use
20 disorder treatment agencies to ensure
21 that—

22 “(I) appropriate notification to
23 child protective services is made in a
24 timely manner;

1 “(II) a plan of safe care is in
2 place, where needed, before the infant
3 is discharged from the birth or health
4 care facility; and

5 “(III) such health and related
6 agency professionals are trained on
7 how to follow such protocols and are
8 aware of the supports that may be
9 provided under a plan of safe care.

10 “(iii) Training health professionals
11 and health system leaders, child welfare
12 workers, substance use disorder treatment
13 agencies, and other related professionals
14 such as home visiting agency staff and law
15 enforcement in relevant topics including—

16 “(I) State mandatory reporting
17 laws and the referral and notification
18 process;

19 “(II) the co-occurrence of preg-
20 nancy and substance use disorder;

21 “(III) the clinical guidance about
22 treating substance use disorder in
23 pregnant and postpartum women;

24 “(IV) appropriate screening and
25 interventions for infants affected by

1 substance use disorder, withdrawal
2 symptoms, or a fetal alcohol spectrum
3 disorder and the requirements under
4 section 106(b)(2)(B)(iii); and

5 “(V) appropriate strategies to ad-
6 dress the mental health needs of the
7 parent and child together.

8 “(iv) Establishing partnerships, agree-
9 ments, or memoranda of understanding be-
10 tween the lead agency and health profes-
11 sionals, health facilities, child welfare pro-
12 fessionals, substance use disorder and
13 mental health disorder treatment pro-
14 grams, early childhood education pro-
15 grams, and maternal and child health and
16 early intervention professionals, including
17 home visiting providers, peer-to-peer recov-
18 ery programs such as parent mentoring
19 programs, and housing agencies to facili-
20 tate the implementation of, and compliance
21 with section 106(b)(2) and clause (ii) of
22 this subparagraph, in areas which may in-
23 clude—

24 “(I) developing a comprehensive,
25 multi-disciplinary assessment and

1 intervention process for infants and
2 their families who are affected by sub-
3 stance use disorder, withdrawal symp-
4 toms, or a fetal alcohol spectrum dis-
5 order, that includes meaningful en-
6 gagement with and takes into account
7 the unique needs of each family and
8 addresses differences between legal,
9 medically supervised substance use,
10 and substance use disorder;

11 “(II) ensuring that treatment ap-
12 proaches for serving infants, pregnant
13 women, and perinatal and postnatal
14 women whose infants may be affected
15 by substance use, withdrawal symp-
16 toms, or a fetal alcohol spectrum dis-
17 order, are designed to, where appro-
18 priate, keep infants with their moth-
19 ers during both inpatient and out-
20 patient treatment; and

21 “(III) increasing access to evi-
22 dence-based medication-assisted treat-
23 ment approved by the Food and Drug
24 Administration, behavioral therapy,
25 and counseling services for the treat-

1 ment of substance use disorders, as
2 appropriate.

3 “(v) Developing and updating systems
4 of technology for improved data collection
5 and monitoring under section
6 106(b)(2)(B)(iii), including existing elec-
7 tronic medical records, to measure the out-
8 comes achieved through the plans of safe
9 care, including monitoring systems to meet
10 the requirements of this Act and submis-
11 sion of performance measures.

12 “(E) REPORTING.—Each State that re-
13 ceives funds under this paragraph, for each
14 year such funds are received, shall submit a re-
15 port to the Secretary, disaggregated by geo-
16 graphic location, economic status, and major
17 racial and ethnic groups, except that such
18 disaggregation shall not be required if the re-
19 sults would reveal personally identifiable infor-
20 mation, on the following:

21 “(i) The number of the infants identi-
22 fied under section 106(b)(2)(B)(ii) who ex-
23 perienced removal due to parental sub-
24 stance use concerns who are reunified with

1 parents, and the length of time between
2 such removal and reunification.

3 “(ii) The number of the infants iden-
4 tified under section 106(b)(2)(B)(ii) who
5 experienced substantiated reports of child
6 abuse or neglect and received differential
7 response while in the care of their birth
8 parents or within 1 year after a reunifica-
9 tion has occurred.

10 “(iii) The number of the infants iden-
11 tified under section 106(b)(2)(B)(ii) who
12 experienced a return to out-of-home care
13 within one year after reunification.

14 “(F) SECRETARY’S REPORT TO CON-
15 GRESS.—The Secretary shall submit an annual
16 report to the Committee on Health, Education,
17 Labor, and Pensions and the Committee on Ap-
18 propriations of the Senate and the Committee
19 on Education and the Workforce and the Com-
20 mittee on Appropriations of the House of Rep-
21 resentatives that includes the information de-
22 scribed in subparagraph (E) and recommenda-
23 tions or observations on the challenges, suc-
24 cesses, and lessons derived from implementation
25 of the grant program.

1 “(G) RESERVATION OF FUNDS.—The Sec-
2 retary shall use the amount reserved under sub-
3 paragraph (B)(i)(I) for the purposes of—

4 “(i) providing technical assistance, in-
5 cluding programs of in-depth technical as-
6 sistance, to additional States, territories,
7 and Indian tribes in accordance with the
8 substance-exposed infant initiative devel-
9 oped by the National Center on Substance
10 Abuse and Child Welfare;

11 “(ii) issuing guidance on the require-
12 ments of this Act with respect to infants
13 born with and identified as being affected
14 by substance use or withdrawal symptoms
15 or fetal alcohol spectrum disorder, as de-
16 scribed in clauses (ii) and (iii) of section
17 106(b)(2)(B), including by—

18 “(I) clarifying key terms; and

19 “(II) disseminating best practices
20 on implementation of plans of safe
21 care, on such topics as differential re-
22 sponse, collaboration and coordina-
23 tion, and identification and delivery of
24 services, for different populations;

1 “(iii) supporting State efforts to de-
 2 velop information technology systems to
 3 manage plans of safe care; and

4 “(iv) preparing the Secretary’s report
 5 to Congress described in subparagraph
 6 (F).

7 “(H) AUTHORIZATION OF APPROPRIA-
 8 TIONS.—To carry out the program under this
 9 paragraph, there are authorized to be appro-
 10 priated \$60,000,000 for each of fiscal years
 11 2019 through 2023.”.

12 (b) DEFINITION.—Section 3 of the Child Abuse Pre-
 13 vention and Treatment Act (42 U.S.C. 5101 note) is
 14 amended—

15 (1) in paragraph (7), by striking “; and” and
 16 inserting a semicolon;

17 (2) by redesignating paragraph (8) as para-
 18 graph (9); and

19 (3) by inserting after paragraph (7) the fol-
 20 lowing:

21 “(8) the term ‘substance use disorder’ means
 22 the abuse of alcohol or other drugs; and”.

1 **SEC. 410. REGULATIONS RELATING TO SPECIAL REGISTRA-**
 2 **TION FOR TELEMEDICINE.**

3 Section 311(h) of the Controlled Substances Act (21
 4 U.S.C. 831(h)) is amended by striking paragraph (2) and
 5 inserting the following:

6 “(2) REGULATIONS.—

7 “(A) IN GENERAL.—Not later than 1 year
 8 after the date of enactment of the Opioid Crisis
 9 Response Act of 2018, in consultation with the
 10 Secretary, and in accordance with the procedure
 11 described in subparagraph (B), the Attorney
 12 General shall promulgate final regulations
 13 specifying—

14 “(i) the limited circumstances in
 15 which a special registration under this sub-
 16 section may be issued; and

17 “(ii) the procedure for obtaining a
 18 special registration under this subsection.

19 “(B) PROCEDURE.—In promulgating final
 20 regulations under subparagraph (A), the Attor-
 21 ney General shall—

22 “(i) issue a notice of proposed rule-
 23 making that includes a copy of the pro-
 24 posed regulations;

1 “(ii) provide a period of not less than
 2 60 days for comments on the proposed reg-
 3 ulations;

4 “(iii) finalize the proposed regulation
 5 not later than 6 months after the close of
 6 the comment period; and

7 “(iv) publish the final regulations not
 8 later than 30 days before the effective date
 9 of the final regulations.”.

10 **SEC. 411. NATIONAL HEALTH SERVICE CORPS BEHAVIORAL**
 11 **AND MENTAL HEALTH PROFESSIONALS PRO-**
 12 **VIDING OBLIGATED SERVICE IN SCHOOLS**
 13 **AND OTHER COMMUNITY-BASED SETTINGS.**

14 Subpart III of part D of title III of the Public Health
 15 Service Act (42 U.S.C. 254*l* et seq.) is amended by adding
 16 at the end the following:

17 **“SEC. 338N. BEHAVIORAL AND MENTAL HEALTH PROFES-**
 18 **SIONALS PROVIDING OBLIGATED SERVICE IN**
 19 **SCHOOLS AND OTHER COMMUNITY-BASED**
 20 **SETTINGS.**

21 “(a) SCHOOLS AND COMMUNITY-BASED SETTINGS.—
 22 An entity to which a Corps member is assigned under sec-
 23 tion 333 may direct such Corps member to provide service
 24 as a behavioral and mental health professional at a school

1 or other community-based setting located in a health pro-
 2 fessional shortage area.

3 “(b) OBLIGATED SERVICE.—

4 “(1) IN GENERAL.—Any service described in
 5 subsection (a) that a Corps member provides may
 6 count towards such Corps member’s completion of
 7 any obligated service requirements under the Schol-
 8 arship Program or the Loan Repayment Program,
 9 subject to any limitation imposed under paragraph
 10 (2).

11 “(2) LIMITATION.—The Secretary may impose
 12 a limitation on the number of hours of service de-
 13 scribed in subsection (a) that a Corps member may
 14 credit towards completing obligated service require-
 15 ments, provided that the limitation allows a member
 16 to credit service described in subsection (a) for not
 17 less than 50 percent of the total hours required to
 18 complete such obligated service requirements.

19 “(c) RULE OF CONSTRUCTION.—The authorization
 20 under subsection (a) shall be notwithstanding any other
 21 provision of this subpart or subpart II.”.

22 **SEC. 412. LOAN REPAYMENT FOR SUBSTANCE USE DIS-**
 23 **ORDER TREATMENT PROVIDERS.**

24 (a) LOAN REPAYMENT FOR SUBSTANCE USE TREAT-
 25 MENT PROVIDERS.—The Secretary of Health and Human

1 Services (referred to in this section as the “Secretary”)
 2 shall enter into contracts under section 338B of the Public
 3 Health Service Act (42 U.S.C. 254l–1) with eligible health
 4 professionals providing substance use disorder treatment
 5 services in substance use disorder treatment facilities, as
 6 defined by the Secretary.

7 (b) PROVISION OF SUBSTANCE USE DISORDER
 8 TREATMENT.—In carrying out the activities described in
 9 subsection (a)—

10 (1) such facilities shall be located in mental
 11 health professional shortage areas designated under
 12 section 332 of the Public Health Service Act (42
 13 U.S.C. 254e);

14 (2) section 331(a)(3)(D) of such Act (42 U.S.C.
 15 254d(a)(3)(D)) shall be applied as if the term “pri-
 16 mary health services” includes health services re-
 17 garding substance use disorder treatment;

18 (3) section 331(a)(3)(E)(i) of such Act (42
 19 U.S.C. 254d(a)(3)(E)(i)) shall be applied as if the
 20 term “behavioral and mental health professionals”
 21 includes masters level, licensed substance use dis-
 22 order treatment counselors; and

23 (4) such professionals and facilities shall pro-
 24 vide—

(A) counseling by a program counselor or other certified professional who is licensed and qualified by education, training, or experience to assess the psychological and sociological background of patients, to contribute to the appropriate treatment plan for the patient, and to monitor progress; and

(B) all drugs approved by the Food and Drug Administration to treat substance use disorders.

(c) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out this section, \$25,000,000 for each of fiscal years 2019 through 2023.

SEC. 413. IMPROVING TREATMENT FOR PREGNANT AND POSTPARTUM WOMEN.

(a) REPORT.—

(1) IN GENERAL.—Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this subsection as the “Secretary”) shall submit to the appropriate committees of Congress and make available to the public on the internet website of the Department of Health and Human Services a report regarding the implementation of the recommendations in the strategy relating to prenatal opioid use,

1 including neonatal abstinence syndrome, developed
 2 pursuant to section 2 of the Protecting Our Infants
 3 Act of 2015 (Public Law 114–91). Such report shall
 4 include—

5 (A) an update on the implementation of
 6 the recommendations in the strategy, including
 7 information regarding the agencies involved in
 8 the implementation; and

9 (B) information on additional funding or
 10 authority the Secretary requires, if any, to im-
 11 plement the strategy, which may include au-
 12 thorities needed to coordinate implementation
 13 of such strategy across the Department of
 14 Health and Human Services.

15 (2) PERIODIC UPDATES.—The Secretary shall
 16 periodically update the report under paragraph (1).

17 (b) RESIDENTIAL TREATMENT PROGRAMS FOR
 18 PREGNANT AND POSTPARTUM WOMEN.—Section 508(s)
 19 of the Public Health Service Act (42 U.S.C. 290bb–1(s))
 20 is amended by striking “\$16,900,000 for each of fiscal
 21 years 2017 through 2021” and inserting “\$29,931,000 for
 22 each of fiscal years 2019 through 2023”.

1 **SEC. 414. EARLY INTERVENTIONS FOR PREGNANT WOMEN**
2 **AND INFANTS.**

3 (a) DEVELOPMENT OF EDUCATIONAL MATERIALS BY
4 CENTER FOR SUBSTANCE ABUSE PREVENTION.—Section
5 515(b) of the Public Health Service Act (42 U.S.C.
6 290bb–21(b)) is amended—

7 (1) in paragraph (13), by striking “and” at the
8 end;

9 (2) in paragraph (14), by striking the period at
10 the end and inserting “; and”; and

11 (3) by adding at the end the following:

12 “(15) in cooperation with relevant stakeholders
13 and the Director of the Centers for Disease Control
14 and Prevention, develop educational materials for
15 clinicians to use with pregnant women for shared de-
16 cisionmaking regarding pain management during
17 pregnancy.”.

18 (b) GUIDELINES AND RECOMMENDATIONS BY CEN-
19 TER FOR SUBSTANCE ABUSE TREATMENT.—Section
20 507(b) of the Public Health Service Act (42 U.S.C.
21 290bb(b)) is amended—

22 (1) in paragraph (13), by striking “and” at the
23 end;

24 (2) in paragraph (14), by striking the period at
25 the end and inserting a semicolon; and

26 (3) by adding at the end the following:

1 “(15) in cooperation with the Secretary, imple-
 2 ment and disseminate, as appropriate, the rec-
 3 ommendations in the report entitled ‘Protecting Our
 4 Infants Act: Final Strategy’ issued by the Depart-
 5 ment of Health and Human Services in 2017; and”.

6 (c) SUPPORT OF PARTNERSHIPS BY CENTER FOR
 7 SUBSTANCE ABUSE TREATMENT.—Section 507(b) of the
 8 Public Health Service Act (42 U.S.C. 290bb(b)), as
 9 amended by subsection (b), is further amended by adding
 10 at the end the following:

11 “(16) in cooperation with relevant stakeholders,
 12 support public-private partnerships to assist with
 13 education about, and support with respect to, sub-
 14 stance use disorder for pregnant women and health
 15 care providers who treat pregnant women and ba-
 16 bies.”.

17 **TITLE V—PREVENTION**

18 **SEC. 501. STUDY ON PRESCRIBING LIMITS.**

19 Not later than 2 years after the date of enactment
 20 of this Act, the Secretary of Health and Human Services,
 21 in consultation with the Attorney General, shall submit to
 22 the Committee on Health, Education, Labor, and Pen-
 23 sions of the Senate and the Committee on Energy and
 24 Commerce of the House of Representatives a report on
 25 the impact of Federal and State laws and regulations that

1 limit the length, quantity, or dosage of opioid prescrip-
2 tions. Such report shall address—

3 (1) the impact of such limits on—

4 (A) the incidence and prevalence of over-
5 dose related to prescription opioids;

6 (B) the incidence and prevalence of over-
7 dose related to illicit opioids;

8 (C) the prevalence of opioid use disorders;
9 and

10 (D) medically appropriate use of, and ac-
11 cess to, opioids, including any impact on travel
12 expenses and pain management outcomes for
13 patients, whether such limits are associated
14 with significantly higher rates of negative
15 health outcomes, including suicide, and whether
16 the impact of such limits differs based on clin-
17 ical indication for which opioids are prescribed;

18 (2) whether such limits lead to a significant in-
19 crease in burden for prescribers of opioids or pre-
20 scribers of treatments for opioid use disorder, in-
21 cluding any impact on patient access to treatment,
22 and whether any such burden is mitigated by any
23 factors such as electronic prescribing; and

24 (3) the impact of such limits on diversion or
25 misuse of any controlled substance in schedule II,

1 III, or IV of section 202(c) of the Controlled Sub-
2 stances Act (21 U.S.C. 812(c)).

3 **SEC. 502. PROGRAMS FOR HEALTH CARE WORKFORCE.**

4 (a) PROGRAM FOR EDUCATION AND TRAINING IN
5 PAIN CARE.—Section 759 of the Public Health Service
6 Act (42 U.S.C. 294i) is amended—

7 (1) in subsection (a), by inserting “nonprofit”
8 after “private”;

9 (2) in subsection (b)—

10 (A) in the matter preceding paragraph (1),
11 by striking “award may be made under sub-
12 section (a) only if the applicant for the award
13 agrees that the program carried out with the
14 award will include” and inserting “entity receiv-
15 ing an award under this section shall develop a
16 comprehensive education and training plan that
17 includes”;

18 (B) in paragraph (1)—

19 (i) by inserting “preventing,” after
20 “diagnosing,”; and

21 (ii) by inserting “non-addictive med-
22 ical products and non-pharmacologic treat-
23 ments and” after “including”;

24 (C) in paragraph (2)—

1 (i) by inserting “Federal, State, and
2 local” after “applicable”; and

3 (ii) by striking “the degree to which”
4 and all that follows through “effective pain
5 care” and inserting “opioids”;

6 (D) in paragraph (3), by inserting “and,
7 as appropriate, non-pharmacotherapy” before
8 the semicolon;

9 (E) in paragraph (4)—

10 (i) by inserting “any” before “cul-
11 tural”; and

12 (ii) by striking “; and” and inserting
13 “;”;

14 (F) in paragraph (5), by striking “provi-
15 sion of pain care.” and inserting “scientific
16 basis of pain and the provision of pain care, in-
17 cluding through non-addictive medical products
18 and non-pharmacologic treatments; and”; and

19 (G) by adding at the end the following:

20 “(6) the dangers of opioid abuse, detection of
21 early warning signs of opioid use disorders, and safe
22 disposal options for prescription medications, includ-
23 ing such options provided by law enforcement, or
24 other innovative deactivation mechanisms.”;

1 (3) in subsection (d), by inserting “prevention,”
 2 after “diagnosis,”; and

3 (4) in subsection (e), by striking “2010 through
 4 2012” and inserting “2019 through 2023”.

5 (b) MENTAL AND BEHAVIORAL HEALTH EDUCATION
 6 AND TRAINING PROGRAM.—Section 756(a) of the Public
 7 Health Service Act (42 U.S.C. 294e–1(a)) is amended—

8 (1) in paragraph (1), by inserting “, trauma,”
 9 after “focus on child and adolescent mental health”;
 10 and

11 (2) in paragraphs (2) and (3), by inserting
 12 “trauma-informed care and” before “substance use
 13 disorder prevention and treatment services”.

14 **SEC. 503. EDUCATION AND AWARENESS CAMPAIGNS.**

15 Section 102 of the Comprehensive Addiction and Re-
 16 covery Act of 2016 (Public Law 114–198) is amended—

17 (1) by amending subsection (a) to read as fol-
 18 lows:

19 “(a) IN GENERAL.—The Secretary of Health and
 20 Human Services, acting through the Director of the Cen-
 21 ters for Disease Control and Prevention and in coordina-
 22 tion with the heads of other departments and agencies,
 23 shall advance education and awareness regarding the risks
 24 related to misuse and abuse of opioids, as appropriate,
 25 which may include developing or improving existing pro-

1 grams, conducting activities, and awarding grants that ad-
2 vance the education and awareness of—

3 “(1) the public, including patients and con-
4 sumers;

5 “(2) patients, consumers, and other appropriate
6 members of the public, regarding such risks related
7 to unused opioids and the dispensing options under
8 section 309(f) of the Controlled Substances Act, as
9 applicable;

10 “(3) providers, which may include—

11 “(A) providing for continuing education on
12 appropriate prescribing practices;

13 “(B) education related to applicable State
14 or local prescriber limit laws, information on
15 the use of non-addictive or non-opioid alter-
16 natives for pain management, and the use of
17 overdose reversal drugs, as appropriate;

18 “(C) disseminating and improving the use
19 of evidence-based opioid prescribing guidelines
20 across relevant health care settings, as appro-
21 priate, and updating guidelines as necessary;

22 “(D) implementing strategies, such as best
23 practices, to encourage and facilitate the use of
24 prescriber guidelines, in accordance with State
25 and local law; and

1 “(E) disseminating information to pro-
 2 viders about prescribing options for controlled
 3 substances, including such options under sec-
 4 tion 309(f) of the Controlled Substances Act, as
 5 applicable; and
 6 “(4) other appropriate entities.”; and
 7 (2) in subsection (b)—

8 (A) by striking “opioid abuse” each place
 9 such term appears and inserting “opioid misuse
 10 and abuse”; and

11 (B) in paragraph (2), by striking “safe dis-
 12 posal of prescription medications and other”
 13 and inserting “non-addictive or non-opioid
 14 treatment options, safe disposal options for pre-
 15 scription medications, and other applicable”.

16 **SEC. 504. ENHANCED CONTROLLED SUBSTANCE**
 17 **OVERDOSES DATA COLLECTION, ANALYSIS,**
 18 **AND DISSEMINATION.**

19 Part J of title III of the Public Health Service Act
 20 is amended by inserting after section 392 (42 U.S.C.
 21 280b–1) the following:

1 **“SEC. 392A. ENHANCED CONTROLLED SUBSTANCE**
2 **OVERDOSES DATA COLLECTION, ANALYSIS,**
3 **AND DISSEMINATION.**

4 “(a) IN GENERAL.—The Director of the Centers for
5 Disease Control and Prevention, using the authority pro-
6 vided to the Director under section 392, may—

7 “(1) to the extent practicable, carry out and ex-
8 pand any controlled substance overdose data collec-
9 tion, analysis, and dissemination activity described
10 in subsection (b);

11 “(2) provide training and technical assistance
12 to States, localities, and Indian tribes for the pur-
13 pose of carrying out any such activity; and

14 “(3) award grants to States, localities, and In-
15 dian tribes for the purpose of carrying out any such
16 activity.

17 “(b) CONTROLLED SUBSTANCE OVERDOSE DATA
18 COLLECTION AND ANALYSIS ACTIVITIES.—A controlled
19 substance overdose data collection, analysis, and dissemi-
20 nation activity described in this subsection is any of the
21 following activities:

22 “(1) Improving the timeliness of reporting ag-
23 gregate data to the public, including data on fatal
24 and nonfatal controlled substance overdoses.

25 “(2) Enhancing the comprehensiveness of con-
26 trolled substance overdose data by collecting infor-

1 mation on such overdoses from appropriate sources
2 such as toxicology reports, death scene investiga-
3 tions, and emergency department services.

4 “(3) Modernizing the system for coding causes
5 of death related to controlled substance overdoses to
6 use an electronic-based system.

7 “(4) Using data to help identify risk factors as-
8 sociated with controlled substance overdoses, includ-
9 ing the delivery of certain health care services.

10 “(5) Supporting entities involved in reporting
11 information on controlled substance overdoses, such
12 as coroners and medical examiners, to improve accu-
13 rate testing and reporting of causes and contributing
14 factors of such overdoses, and analysis of various
15 opioid analogues to controlled substances overdoses.

16 “(6) Working to enable and encourage the ac-
17 cess, exchange, and use of data regarding controlled
18 substances overdoses among data sources and enti-
19 ties.

20 “(c) CONTROLLED SUBSTANCE DEFINED.—In this
21 section, the term ‘controlled substance’ has the meaning
22 given that term in section 102 of the Controlled Sub-
23 stances Act.”.

1 **SEC. 505. PREVENTING OVERDOSES OF CONTROLLED SUB-**
2 **STANCES.**

3 Part J of title III of the Public Health Service Act
4 (42 U.S.C. 280b et seq.), as amended by section 504, is
5 further amended by inserting after section 392A the fol-
6 lowing:

7 **“SEC. 392B. PREVENTING OVERDOSES OF CONTROLLED**
8 **SUBSTANCES.**

9 “(a) PREVENTION ACTIVITIES.—

10 “(1) IN GENERAL.—The Director of the Cen-
11 ters for Disease Control and Prevention (referred to
12 in this section as the ‘Director’), using the authority
13 provided to the Director under section 392, may—

14 “(A) to the extent practicable, carry out
15 and expand any prevention activity described in
16 paragraph (2);

17 “(B) provide training and technical assist-
18 ance to States, localities, and Indian tribes to
19 carrying out any such activity; and

20 “(C) award grants to States, localities, and
21 tribes for the purpose of carrying out any such
22 activity.

23 “(2) PREVENTION ACTIVITIES.—A prevention
24 activity described in this paragraph is an activity to
25 improve the efficiency and use of a new or currently
26 operating prescription drug monitoring program—

1 “(A) encouraging all authorized users (as
2 specified by the State or other entity) to reg-
3 ister with and use the program;

4 “(B) enabling such users to access any
5 data updates in as close to real-time as prac-
6 ticable;

7 “(C) providing for a mechanism for the
8 program to notify authorized users of any po-
9 tential misuse or abuse of controlled substances
10 and any detection of inappropriate prescribing
11 practices relating to such substances;

12 “(D) encouraging the analysis of prescrip-
13 tion drug monitoring data for purposes of pro-
14 viding de-identified, aggregate reports based on
15 such analysis to State public health agencies,
16 State licensing boards, and other appropriate
17 State agencies, as permitted under applicable
18 Federal and State law and the policies of the
19 prescription drug monitoring program and not
20 containing any protected health information, to
21 prevent inappropriate prescribing, drug diver-
22 sion, or abuse and misuse of controlled sub-
23 stances, and to facilitate better coordination
24 among agencies;

1 “(E) enhancing interoperability between
 2 the program and any health information tech-
 3 nology (including certified health information
 4 technology), including by integrating program
 5 data into such technology;

6 “(F) updating program capabilities to re-
 7 spond to technological innovation for purposes
 8 of appropriately addressing the occurrence and
 9 evolution of controlled substance overdoses; and

10 “(G) facilitating and encouraging data ex-
 11 change between the program and the prescrip-
 12 tion drug monitoring programs of other States.

13 “(b) ADDITIONAL GRANTS.—The Director may
 14 award grants to States, localities, and Indian tribes—

15 “(1) to carry out innovative projects for grant-
 16 ees to rapidly respond to controlled substance mis-
 17 use, abuse, and overdoses, including changes in pat-
 18 terns of controlled substance use; and

19 “(2) for any other evidence-based activity for
 20 preventing controlled substance misuse, abuse, and
 21 overdoses as the Director determines appropriate.

22 “(c) RESEARCH.—The Director may conduct studies
 23 and evaluations to address substance use disorders, in-
 24 cluding preventing substance use disorders or other re-
 25 lated topics the Director determines appropriate.

1 “(d) PUBLIC AND PRESCRIBER EDUCATION.—Pursu-
 2 ant to section 102 of the Comprehensive Addiction and
 3 Recovery Act of 2016, the Director may advance the edu-
 4 cation and awareness of prescribers and the public regard-
 5 ing the risk of abuse of prescription opioids.

6 “(e) CONTROLLED SUBSTANCE DEFINED.—In this
 7 section, the term ‘controlled substance’ has the meaning
 8 given that term in section 102 of the Controlled Sub-
 9 stances Act.

10 “(f) AUTHORIZATION OF APPROPRIATIONS.—For
 11 purposes of carrying out this section, section 392A of this
 12 Act, and section 102 of the Comprehensive Addiction and
 13 Recovery Act of 2016, there is authorized to be appro-
 14 priated \$486,000,000 for each of fiscal years 2019
 15 through 2024.”.

16 **SEC. 506. CDC SURVEILLANCE AND DATA COLLECTION FOR**
 17 **CHILD, YOUTH, AND ADULT TRAUMA.**

18 (a) DATA COLLECTION.—The Director of the Centers
 19 for Disease Control and Prevention (referred to in this
 20 section as the “Director”) may, in cooperation with the
 21 States, collect and report data on adverse childhood expe-
 22 riences through the Behavioral Risk Factor Surveillance
 23 System, the Youth Risk Behavior Surveillance System,
 24 and other relevant public health surveys or questionnaires.

1 (b) TIMING.—The collection of data under subsection
 2 (a) may occur in fiscal year 2019 and every 2 years there-
 3 after.

4 (c) DATA FROM TRIBAL AND RURAL AREAS.—The
 5 Director shall encourage each State that participates in
 6 collecting and reporting data under subsection (a) to col-
 7 lect and report data from tribal and rural areas within
 8 such State, in order to generate a statistically reliable rep-
 9 resentation of such areas.

10 (d) AUTHORIZATION OF APPROPRIATIONS.—To carry
 11 out this section, there are authorized to be appropriated
 12 such sums as may be necessary for the period of fiscal
 13 years 2019 through 2021.

14 **SEC. 507. REAUTHORIZATION OF NASPER.**

15 Section 399O of the Public Health Service Act (42
 16 U.S.C. 280g–3) is amended—

17 (1) in subsection (a)—

18 (A) in paragraph (1), in the matter pre-
 19 ceding subparagraph (A), by striking “Adminis-
 20 trator of the Substance Abuse and Mental
 21 Health Services Administration and Director of
 22 the Centers for Disease Control and Preven-
 23 tion” and inserting “Director of the Centers for
 24 Disease Control and Prevention and the Assist-

1 ant Secretary for Mental Health and Substance
2 Use Disorders”; and

3 (B) by adding at the end the following:

4 “(4) STATES AND LOCAL GOVERNMENTS.—

5 “(A) IN GENERAL.—In the case of a State
6 that does not have a prescription drug moni-
7 toring program, a county or other unit of local
8 government within the State that has a pre-
9 scription drug monitoring program shall be
10 treated as a State for purposes of this section,
11 including for purposes of eligibility for grants
12 under paragraph (1).

13 “(B) PLAN FOR INTEROPERABILITY.—For
14 purposes of meeting the interoperability re-
15 quirements under subsection (c)(3), a county or
16 other unit of local government shall submit a
17 plan outlining the methods such county or unit
18 of local government will use to ensure the capa-
19 bility of data sharing with other counties and
20 units of local government within the State and
21 with other States, as applicable.”;

22 (2) in subsection (c)—

23 (A) in paragraph (1)(A)(iii)—

1 (i) by inserting “as such standards
2 become available,” after “interoperability
3 standards,”; and

4 (ii) by striking “generated or identi-
5 fied by the Secretary or his or her des-
6 ignee” and inserting “recognized by the
7 Office of the National Coordinator for
8 Health Information Technology”; and

9 (B) in paragraph (3)(A), by inserting “in-
10 cluding electronic health records,” after “tech-
11 nology systems,”;

12 (3) in subsection (d)(1), by striking “not later
13 than 1 week after the date of such dispensing” and
14 inserting “in as close to real time as practicable”;

15 (4) in subsection (f)(1)(D), by striking “med-
16 icaid” and inserting “Medicaid”;

17 (5) in subsection (i), by inserting “, in collabo-
18 ration with the National Coordinator for Health In-
19 formation Technology and the Director of the Na-
20 tional Institute of Standards and Technology,” after
21 “The Secretary”; and

22 (6) in subsection (n), by striking “2021” and
23 inserting “2026”.

24 **SEC. 508. JESSIE’S LAW.**

25 (a) BEST PRACTICES.—

1 (1) IN GENERAL.—Not later than 1 year after
2 the date of enactment of this Act, the Secretary of
3 Health and Human Services (referred to in this sec-
4 tion as the “Secretary”), in consultation with appro-
5 priate stakeholders, including a patient with a his-
6 tory of opioid use disorder, an expert in electronic
7 health records, an expert in the confidentiality of pa-
8 tient health information and records, and a health
9 care provider, shall identify or facilitate the develop-
10 ment of best practices regarding—

11 (A) the circumstances under which infor-
12 mation that a patient has provided to a health
13 care provider regarding such patient’s history of
14 opioid use disorder should, only at the patient’s
15 request, be prominently displayed in the med-
16 ical records (including electronic health records)
17 of such patient;

18 (B) what constitutes the patient’s request
19 for the purpose described in subparagraph (A);
20 and

21 (C) the process and methods by which the
22 information should be so displayed.

23 (2) DISSEMINATION.—The Secretary shall dis-
24 seminate the best practices developed under para-

1 graph (1) to health care providers and State agen-
2 cies.

3 (b) REQUIREMENTS.—In identifying or facilitating
4 the development of best practices under subsection (a), as
5 applicable, the Secretary, in consultation with appropriate
6 stakeholders, shall consider the following:

7 (1) The potential for addiction relapse or over-
8 dose, including overdose death, when opioid medica-
9 tions are prescribed to a patient recovering from
10 opioid use disorder.

11 (2) The benefits of displaying information
12 about a patient's opioid use disorder history in a
13 manner similar to other potentially lethal medical
14 concerns, including drug allergies and contraindica-
15 tions.

16 (3) The importance of prominently displaying
17 information about a patient's opioid use disorder
18 when a physician or medical professional is pre-
19 scribing medication, including methods for avoiding
20 alert fatigue in providers.

21 (4) The importance of a variety of appropriate
22 medical professionals, including physicians, nurses,
23 and pharmacists, having access to information de-
24 scribed in this section when prescribing or dis-

1 pensing opioid medication, consistent with Federal
2 and State laws and regulations.

3 (5) The importance of protecting patient pri-
4 vacy, including the requirements related to consent
5 for disclosure of substance use disorder information
6 under all applicable laws and regulations.

7 (6) All applicable Federal and State laws and
8 regulations.

9 **SEC. 509. DEVELOPMENT AND DISSEMINATION OF MODEL**
10 **TRAINING PROGRAMS FOR SUBSTANCE USE**
11 **DISORDER PATIENT RECORDS.**

12 (a) INITIAL PROGRAMS AND MATERIALS.—Not later
13 than 1 year after the date of the enactment of this Act,
14 the Secretary of Health and Human Services (referred to
15 in this section as the “Secretary”), in consultation with
16 appropriate experts, shall identify the following model pro-
17 grams and materials (or if no such programs or materials
18 exist, recognize private or public entities to develop and
19 disseminate such programs and materials):

20 (1) Model programs and materials for training
21 health care providers (including physicians, emer-
22 gency medical personnel, psychiatrists, psychologists,
23 counselors, therapists, nurse practitioners, physician
24 assistants, behavioral health facilities and clinics,
25 care managers, and hospitals, including individuals

1 such as general counsels or regulatory compliance
2 staff who are responsible for establishing provider
3 privacy policies) concerning the permitted uses and
4 disclosures, consistent with the standards and regu-
5 lations governing the privacy and security of sub-
6 stance use disorder patient records promulgated by
7 the Secretary under section 543 of the Public
8 Health Service Act (42 U.S.C. 290dd-2) for the
9 confidentiality of patient records.

10 (2) Model programs and materials for training
11 patients and their families regarding their rights to
12 protect and obtain information under the standards
13 and regulations described in paragraph (1).

14 (b) REQUIREMENTS.—The model programs and ma-
15 terials described in paragraphs (1) and (2) of subsection
16 (a) shall address circumstances under which disclosure of
17 substance use disorder patient records is needed to—

18 (1) facilitate communication between substance
19 use disorder treatment providers and other health
20 care providers to promote and provide the best pos-
21 sible integrated care;

22 (2) avoid inappropriate prescribing that can
23 lead to dangerous drug interactions, overdose, or re-
24 lapse; and

1 (3) notify and involve families and caregivers
2 when individuals experience an overdose.

3 (c) PERIODIC UPDATES.—The Secretary shall—

4 (1) periodically review and update the model
5 program and materials identified or developed under
6 subsection (a); and

7 (2) disseminate such updated programs and
8 materials to the individuals described in subsection
9 (a)(1).

10 (d) INPUT OF CERTAIN ENTITIES.—In identifying,
11 reviewing, or updating the model programs and materials
12 under this section, the Secretary shall solicit the input of
13 relevant stakeholders.

14 (e) AUTHORIZATION OF APPROPRIATIONS.—There is
15 authorized to be appropriated to carry out this section,
16 such sums as may be necessary for each of fiscal years
17 2019 through 2023.

18 **SEC. 510. COMMUNICATION WITH FAMILIES DURING EMER-**
19 **GENCIES.**

20 (a) PROMOTING AWARENESS OF AUTHORIZED DIS-
21 CLOSURES DURING EMERGENCIES.—The Secretary of
22 Health and Human Services shall annually notify health
23 care providers regarding permitted disclosures during
24 emergencies, including overdoses, of certain health infor-

1 mation to families and caregivers under Federal health
 2 care privacy laws and regulations.

3 (b) USE OF MATERIAL.—For the purposes of car-
 4 rying out subsection (a), the Secretary of Health and
 5 Human Services may use material produced under section
 6 509 of this Act or under section 11004 of the 21st Cen-
 7 tury Cures Act (42 U.S.C. 1320d–2 note).

8 **SEC. 511. PRENATAL AND POSTNATAL HEALTH.**

9 Section 317L of the Public Health Service Act (42
 10 U.S.C. 247b–13) is amended—

11 (1) in subsection (a)—

12 (A) by amending paragraph (1) to read as
 13 follows:

14 “(1) to collect, analyze, and make available data
 15 on prenatal smoking, alcohol and substance abuse
 16 and misuse, including—

17 “(A) data on—

18 “(i) the incidence, prevalence, and im-
 19 plications of such activities; and

20 “(ii) the incidence and prevalence of
 21 implications and outcomes, including neo-
 22 natal abstinence syndrome and other out-
 23 comes associated with such activities; and

24 “(B) to inform such analysis, additional in-
 25 formation or data on family health history,

1 medication exposures during pregnancy, demo-
 2 graphic information, such as race, ethnicity, ge-
 3 ographic location, and family history, and other
 4 relevant information, as appropriate;”;

5 (B) in paragraph (2)—

6 (i) by striking “prevention of” and in-
 7 serting “prevention and long-term out-
 8 comes associated with”; and

9 (ii) by striking “illegal drug use” and
 10 inserting “substance abuse and misuse”;

11 (C) in paragraph (3), by striking “and ces-
 12 sation programs; and” and inserting “, treat-
 13 ment, and cessation programs;”;

14 (D) in paragraph (4), by striking “illegal
 15 drug use.” and inserting “substance abuse and
 16 misuse; and”; and

17 (E) by adding at the end the following:

18 “(5) to issue public reports on the analysis of
 19 data described in paragraph (1), including analysis
 20 of—

21 “(A) long-term outcomes of children af-
 22 fected by neonatal abstinence syndrome;

23 “(B) health outcomes associated with pre-
 24 natal smoking, alcohol, and substance abuse
 25 and misuse; and

1 “(C) relevant studies, evaluations, or infor-
2 mation the Secretary determines to be appro-
3 priate.”;

4 (2) in subsection (b), by inserting “tribal enti-
5 ties,” after “local governments,”;

6 (3) by redesignating subsection (c) as sub-
7 section (d);

8 (4) by inserting after subsection (b) the fol-
9 lowing:

10 “(c) COORDINATING ACTIVITIES.—To carry out this
11 section, the Secretary may—

12 “(1) provide technical and consultative assist-
13 ance to entities receiving grants under subsection
14 (b);

15 “(2) ensure a pathway for data sharing between
16 States, tribal entities, and the Centers for Disease
17 Control and Prevention;

18 “(3) ensure data collection under this section is
19 consistent with applicable State, Federal, and Tribal
20 privacy laws; and

21 “(4) coordinate with the National Coordinator
22 for Health Information Technology, as appropriate,
23 to assist States and tribes in implementing systems
24 that use standards recognized by such National Co-
25 ordinator, as such recognized standards are avail-

1 able, in order to facilitate interoperability between
 2 such systems and health information technology sys-
 3 tems, including certified health information tech-
 4 nology.”; and

5 (5) in subsection (d), as so redesignated, by
 6 striking “2001 through 2005” and inserting “2019
 7 through 2023”.

8 **SEC. 512. SURVEILLANCE AND EDUCATION REGARDING IN-**
 9 **FECTIONS ASSOCIATED WITH INJECTION**
 10 **DRUG USE AND OTHER RISK FACTORS.**

11 Section 317N of the Public Health Service Act (42
 12 U.S.C. 247b–15) is amended—

13 (1) by amending the section heading to read as
 14 follows: “**SURVEILLANCE AND EDUCATION RE-**
 15 **GARDING INFECTIONS ASSOCIATED WITH IN-**
 16 **JECTION DRUG USE AND OTHER RISK FAC-**
 17 **TORS**”;

18 (2) in subsection (a)—

19 (A) in the matter preceding paragraph (1),
 20 by inserting “activities” before the colon;

21 (B) in paragraph (1)—

22 (i) by inserting “or maintaining” after
 23 “implementing”;

24 (ii) by striking “hepatitis C virus in-
 25 fection (in this section referred to as ‘HCV

infection’))” and inserting “infections commonly associated with injection drug use, including viral hepatitis and human immunodeficiency virus,”; and

(iii) by striking “such infection” and all that follows through the period at the end and inserting “such infections, which may include the reporting of cases of such infections.”;

(C) in paragraph (2), by striking “HCV infection” and all that follows through the period at the end and inserting “infections as a result of injection drug use, receiving blood transfusions prior to July 1992, or other risk factors.”;

(D) in paragraphs (4) and (5), by striking “HCV infection” each place such term appears and inserting “infections described in paragraph (1)”;

(E) in paragraph (5), by striking “pediatricians and other primary care physicians, and obstetricians and gynecologists” and inserting “substance use disorder treatment providers, pediatricians, other primary care providers, and obstetrician-gynecologists”;

1 (3) in subsection (b)—

2 (A) by striking “directly and” and insert-
3 ing “directly or”; and

4 (B) by striking “hepatitis C,” and all that
5 follows through the period at the end and in-
6 serting “infections described in subsection
7 (a)(1).”;

8 (4) by redesignating subsection (c) as sub-
9 section (d);

10 (5) by inserting after subsection (b) the fol-
11 lowing:

12 “(c) DEFINITION.—In this section, the term ‘injec-
13 tion drug use’ means—

14 “(1) intravenous administration of a substance
15 in schedule I of section 202(c) of the Controlled
16 Substances Act;

17 “(2) intravenous administration of a substance
18 in schedule II, III, IV, or V of section 202(c) of the
19 Controlled Substances Act that has not been ap-
20 proved for intravenous use under section 505 of the
21 Federal Food, Drug and Cosmetic Act or section
22 351 of the Public Health Service Act; or

23 “(3) intravenous administration of a substance
24 in schedule II, III, IV, or V of section 202(c) of the

1 Controlled Substances Act that has not been pre-
 2 scribed to the person using the substance.”; and

3 (6) in subsection (d), as so redesignated, by
 4 striking “such sums as may be necessary for each of
 5 the fiscal years 2001 through 2005” and inserting
 6 “\$40,000,000 for each of fiscal years 2019 through
 7 2023”.

8 **SEC. 513. TASK FORCE TO DEVELOP BEST PRACTICES FOR**
 9 **TRAUMA-INFORMED IDENTIFICATION, RE-**
 10 **FERRAL, AND SUPPORT.**

11 (a) ESTABLISHMENT.—There is established a task
 12 force, to be known as the Interagency Task Force on
 13 Trauma-Informed Care (in this section referred to as the
 14 “task force”) that shall identify, evaluate, and make rec-
 15 ommendations regarding best practices with respect to
 16 children and youth, and their families as appropriate, who
 17 have experienced or are at risk of experiencing trauma.

18 (b) MEMBERSHIP.—

19 (1) COMPOSITION.—The task force shall be
 20 composed of the heads of the following Federal de-
 21 partments and agencies, or their designees:

22 (A) The Centers for Medicare & Medicaid
 23 Services.

24 (B) The Substance Abuse and Mental
 25 Health Services Administration.

1 (C) The Agency for Healthcare Research
2 and Quality.

3 (D) The Centers for Disease Control and
4 Prevention.

5 (E) The Indian Health Service.

6 (F) The Department of Veterans Affairs.

7 (G) The National Institutes of Health.

8 (H) The Food and Drug Administration.

9 (I) The Health Resources and Services Ad-
10 ministration.

11 (J) The Department of Defense.

12 (K) The Office of Minority Health.

13 (L) The Administration for Children and
14 Families.

15 (M) The Office of the Assistant Secretary
16 for Planning and Evaluation.

17 (N) The Office for Civil Rights at the De-
18 partment of Health and Human Services.

19 (O) The Office of Juvenile Justice and De-
20 linquency Prevention of the Department of Jus-
21 tice.

22 (P) The Office of Community Oriented Po-
23licing Services of the Department of Justice.

24 (Q) The Office on Violence Against
25 Women of the Department of Justice.

1 (R) The National Center for Education
2 Evaluation and Regional Assistance of the De-
3 partment of Education.

4 (S) The National Center for Special Edu-
5 cation Research of the Institute of Education
6 Science.

7 (T) The Office of Elementary and Sec-
8 ondary Education of the Department of Edu-
9 cation.

10 (U) The Office for Civil Rights at the De-
11 partment of Education.

12 (V) The Office of Special Education and
13 the Rehabilitative Services of the Department
14 of Education.

15 (W) the Bureau of Indian Affairs of the
16 Department of the Interior.

17 (X) The Veterans Health Administration
18 of the Department of Veterans Affairs.

19 (Y) The Office of Special Needs Assistance
20 Programs of the Department of Housing and
21 Urban Development.

22 (Z) The Office of Head Start of the Ad-
23 ministration for Children and Families.

24 (AA) The Children's Bureau of the Admin-
25 istration for Children and Families.

1 (BB) The Bureau of Indian Education of
2 the Department of the Interior.

3 (CC) Such other Federal agencies as the
4 Secretaries determine to be appropriate.

5 (2) DATE OF APPOINTMENTS.—The heads of
6 Federal departments and agencies shall appoint the
7 corresponding members of the task force not later
8 than 6 months after the date of enactment of this
9 Act.

10 (3) CHAIRPERSON.—The task force shall be
11 chaired by the Assistant Secretary for Mental
12 Health and Substance Use.

13 (c) TASK FORCE DUTIES.—The task force shall—

14 (1) solicit input from stakeholders, including
15 frontline service providers, educators, mental health
16 professionals, researchers, experts in infant, child,
17 and youth trauma, child welfare professionals, and
18 the public, in order to inform the activities under
19 paragraph (2); and

20 (2) identify, evaluate, make recommendations,
21 and update such recommendations not less than an-
22 nually, to the general public, the Secretary of Edu-
23 cation, the Secretary of Health and Human Services,
24 the Secretary of Labor, the Secretary of the Inte-

rior, the Attorney General, and other relevant cabinet Secretaries, and Congress regarding—

(A) a set of evidence-based, evidence-informed, and promising best practices with respect to—

(i) the identification of infants, children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma; and

(ii) the expeditious referral to and implementation of trauma-informed practices and supports that prevent and mitigate the effects of trauma;

(B) a national strategy on how the task force and member agencies will collaborate, prioritize options for, and implement a coordinated approach which may include data sharing and the awarding of grants that support children and their families as appropriate, who have experienced or are at risk of experiencing trauma; and

(C) existing Federal authorities at the Department of Education, Department of Health and Human Services, Department of Justice, Department of Labor, Department of Interior,

1 and other relevant agencies, and specific Fed-
2 eral grant programs to disseminate best prac-
3 tices on, provide training in, or deliver services
4 through, trauma-informed practices, and dis-
5 seminate such information—

6 (i) in writing to relevant program of-
7 fices at such agencies to encourage grant
8 applicants in writing to use such funds,
9 where appropriate, for trauma-informed
10 practices; and

11 (ii) to the general public through the
12 internet website of the task force.

13 (d) BEST PRACTICES.—In identifying, evaluating,
14 and recommending the set of best practices under sub-
15 section (c), the task force shall—

16 (1) include guidelines for providing professional
17 development for front-line services providers, includ-
18 ing school personnel, providers from child- or youth-
19 serving organizations, primary and behavioral health
20 care providers, child welfare and social services pro-
21 viders, family and juvenile court judges and attor-
22 neys, health care providers, individuals who are
23 mandatory reporters of child abuse or neglect,
24 trained nonclinical providers (including peer mentors
25 and clergy), and first responders, in—

1 (A) understanding and identifying early
2 signs and risk factors of trauma in children and
3 youth, and their families as appropriate, includ-
4 ing through screening processes;

5 (B) providing practices to prevent and
6 mitigate the impact of trauma, including by fos-
7 tering safe and stable environments and rela-
8 tionships; and

9 (C) developing and implementing proce-
10 dures or systems that—

11 (i) are designed to quickly refer in-
12 fants, children, youth, and their families as
13 appropriate, who have experienced or are
14 at risk of experiencing trauma to the ap-
15 propriate trauma-informed screening and
16 support, including treatment appropriate
17 to the age of the child, and to ensure such
18 infants, children, youth, and family mem-
19 bers receive such support;

20 (ii) utilize and develop partnerships
21 with local social services organizations,
22 such as organizations serving youth, and
23 clinical mental health or health care service
24 providers with expertise in providing sup-
25 port services (including trauma-informed

and evidence-based treatment appropriate to the age of the child) aimed at preventing or mitigating the effects of trauma;

(iii) educate children and youth to—

(I) understand and identify the signs, effects, or symptoms of trauma; and

(II) build the resilience and coping skills to mitigate the effects of experiencing trauma;

(iv) promote and support multigenerational practices that assist parents, foster parents, and kinship and other caregivers in accessing resources related to, and developing environments conducive to, the prevention and mitigation of trauma; and

(v) collect and utilize data from screenings, referrals, or the provision of services and supports, conducted in the covered settings, to evaluate and improve processes for trauma-informed support and outcomes that are culturally sensitive, lin-

1 guistically appropriate, and specific to age
2 ranges and sex, as applicable; and

3 (2) recommend best practices that are designed
4 to avoid unwarranted custody loss or criminal pen-
5 alties for parents or guardians in connection with in-
6 fants, children, and youth who have experienced or
7 are at risk of experiencing trauma.

8 (e) OPERATING PLAN.—Not later than 1 year after
9 the date of enactment of this Act, the task force shall hold
10 the first meeting. Not later than 2 years after such date
11 of enactment, the task force shall submit to the Secretary
12 of Education, Secretary of Health and Human Services,
13 Secretary of Labor, Secretary of the Interior, the Attorney
14 General, and Congress an operating plan for carrying out
15 the activities of the task force described in paragraphs (2)
16 and (3) of subsection (c). Such operating plan shall in-
17 clude—

18 (1) a list of specific activities that the task
19 force plans to carry out for purposes of carrying out
20 duties described in subsection (c)(2), which may in-
21 clude public engagement;

22 (2) a plan for carrying out the activities under
23 paragraphs (2) and (3) of subsection (c);

24 (3) a list of members of the task force and
25 other individuals who are not members of the task

1 force that may be consulted to carry out such activi-
2 ties;

3 (4) an explanation of Federal agency involve-
4 ment and coordination needed to carry out such ac-
5 tivities, including any statutory or regulatory bar-
6 riers to such coordination;

7 (5) a budget for carrying out such activities;
8 and

9 (6) other information that the task force deter-
10 mines appropriate.

11 (f) FINAL REPORT.—Not later than 3 years after the
12 date of the first meeting of the task force, the task force
13 shall submit to the general public, Secretary of Education,
14 Secretary of Health and Human Services, Secretary of
15 Labor, Secretary of the Interior, the Attorney General,
16 and other relevant cabinet Secretaries, and Congress, a
17 final report containing all of the findings and rec-
18 ommendations required under this section.

19 (g) AUTHORIZATION OF APPROPRIATIONS.—To carry
20 out this section, there are authorized to be appropriated
21 such sums as may be necessary for each of fiscal years
22 2019 through 2022.

23 (h) SUNSET.—The task force shall on the date that
24 is 60 days after the submission of the final report under
25 subsection (f), but not later than September 30, 2022.

1 **SEC. 514. GRANTS TO IMPROVE TRAUMA SUPPORT SERV-**
2 **ICES AND MENTAL HEALTH CARE FOR CHIL-**
3 **DREN AND YOUTH IN EDUCATIONAL SET-**
4 **TINGS.**

5 (a) GRANTS, CONTRACTS, AND COOPERATIVE
6 AGREEMENTS AUTHORIZED.—The Secretary, in coordina-
7 tion with the Director of Substance Abuse and Mental
8 Health Services Administration, is authorized to award
9 grants to, or enter into contracts or cooperative agree-
10 ments with, State educational agencies, local educational
11 agencies, Head Start agencies (including Early Head
12 Start agencies), State or local agencies that administer
13 public preschool programs, Indian tribes or their tribal
14 educational agencies, a school operated by the Bureau of
15 Indian Education, a Regional Corporation (as defined in
16 section 3 of the Alaska Native Claims Settlement Act (43
17 U.S.C. 1602)), or a Native Hawaiian educational organi-
18 zation (as defined in section 6207 of the Elementary and
19 Secondary Education Act of 1965 (20 U.S.C. 7517)), for
20 the purpose of increasing student access to evidence-based
21 trauma support services and mental health care by devel-
22 oping innovative initiatives, activities, or programs to link
23 local school systems with local trauma-informed support
24 and mental health systems, including those under the In-
25 dian Health Service.

1 (b) DURATION.—With respect to a grant, contract,
2 or cooperative agreement awarded or entered into under
3 this section, the period during which payments under such
4 grant, contract or agreement are made to the recipient
5 may not exceed 4 years.

6 (c) USE OF FUNDS.—An entity that receives a grant,
7 contract, or cooperative agreement under this section shall
8 use amounts made available through such grant, contract,
9 or cooperative agreement for evidence-based or promising
10 activities, which shall include any of the following:

11 (1) Collaborative efforts between school-based
12 service systems and trauma-informed support and
13 mental health service systems to provide, develop, or
14 improve prevention, screening, referral, and treat-
15 ment services to students, such as by providing uni-
16 versal trauma screenings to identify students in need
17 of specialized support.

18 (2) To implement multi-tiered positive behav-
19 ioral interventions and supports, or other trauma-in-
20 formed models of support.

21 (3) To provide professional development to
22 teachers, teacher assistants, school leaders, special-
23 ized instructional support personnel, and mental
24 health professionals that—

1 (A) fosters safe and stable learning envi-
2 ronments that prevent and mitigate the effects
3 of trauma, including through social and emo-
4 tional learning;

5 (B) improves school capacity to identify,
6 refer, and provide services to students in need
7 of trauma support or behavioral health services;
8 or

9 (C) reflects the best practices developed by
10 the Interagency Task Force on Trauma-In-
11 formed Care established under section 513.

12 (4) Engaging families and communities in ef-
13 forts to increase awareness of child and youth trau-
14 ma, which may include sharing best practices with
15 law enforcement regarding trauma-informed care
16 and working with mental health professionals to pro-
17 vide interventions, as well as longer term coordi-
18 nated care within the community for children and
19 youth who have experienced trauma and their fami-
20 lies.

21 (5) To provide technical assistance to school
22 systems and mental health agencies.

23 (6) To evaluate the effectiveness of the program
24 carried out under this section in increasing student

1 access to evidence-based trauma support services
2 and mental health care.

3 (d) APPLICATIONS.—To be eligible to receive a grant,
4 contract, or cooperative agreement under this section, an
5 entity described in subsection (a) shall submit an applica-
6 tion to the Secretary at such time, in such manner, and
7 containing such information as the Secretary may reason-
8 ably require, which shall include the following:

9 (1) A description of the program to be funded
10 under the grant, contract, or cooperative agreement,
11 including how such program will increase access to
12 evidence-based trauma support services and mental
13 health care for students, and, as applicable, the fam-
14 ilies of the students.

15 (2) A description of how the program will pro-
16 vide linguistically appropriate and culturally com-
17 petent services.

18 (3) A description of how the program will sup-
19 port students and the school in improving the school
20 climate in order to support an environment condu-
21 cive to learning.

22 (4) An assurance that—

23 (A) persons providing services under the
24 grant, contract, or cooperative agreement are
25 adequately trained to provide such services; and

1 (B) teachers, school leaders, administra-
2 tors, specialized instructional support personnel,
3 representatives of local Indian tribes as appro-
4 priate, other school personnel, and parents or
5 guardians of students participating in services
6 under this section will be engaged and involved
7 in the design and implementation of the serv-
8 ices.

9 (5) A description of how the applicant will sup-
10 port and integrate existing school-based services
11 with the program in order to provide mental health
12 services for students, as appropriate.

13 (e) INTERAGENCY AGREEMENTS.—

14 (1) DESIGNATION OF LEAD AGENCY.—A recipi-
15 ent of a grant, contract, or cooperative agreement
16 under this section shall designate a lead agency to
17 direct the establishment of an interagency agreement
18 among local educational agencies, juvenile justice au-
19 thorities, mental health agencies, child welfare agen-
20 cies, and other relevant entities in the State, in col-
21 laboration with local entities, such as Indian tribes.

22 (2) CONTENTS.—The interagency agreement
23 shall ensure the provision of the services described
24 in subsection (c), specifying with respect to each
25 agency, authority, or entity—

1 (A) the financial responsibility for the serv-
2 ices;

3 (B) the conditions and terms of responsi-
4 bility for the services, including quality, ac-
5 countability, and coordination of the services;
6 and

7 (C) the conditions and terms of reimburse-
8 ment among the agencies, authorities, or enti-
9 ties that are parties to the interagency agree-
10 ment, including procedures for dispute resolu-
11 tion.

12 (f) EVALUATION.—The Secretary shall reserve not to
13 exceed 3 percent of the funds made available under sub-
14 section (l) for each fiscal year to—

15 (1) conduct a rigorous, independent evaluation
16 of the activities funded under this section; and

17 (2) disseminate and promote the utilization of
18 evidence-based practices regarding trauma support
19 services and mental health care.

20 (g) DISTRIBUTION OF AWARDS.—The Secretary shall
21 ensure that grants, contracts, and cooperative agreements
22 awarded or entered into under this section are equitably
23 distributed among the geographical regions of the United
24 States and among tribal, urban, suburban, and rural pop-
25 ulations.

1 (h) RULE OF CONSTRUCTION.—Nothing in this sec-
 2 tion shall be construed—

3 (1) to prohibit an entity involved with a pro-
 4 gram carried out under this section from reporting
 5 a crime that is committed by a student to appro-
 6 priate authorities; or

7 (2) to prevent Federal, State, and tribal law en-
 8 forcement and judicial authorities from exercising
 9 their responsibilities with regard to the application
 10 of Federal, tribal, and State law to crimes com-
 11 mitted by a student.

12 (i) SUPPLEMENT, NOT SUPPLANT.—Any services
 13 provided through programs carried out under this section
 14 shall supplement, and not supplant, existing mental health
 15 services, including any special education and related serv-
 16 ices provided under the Individuals with Disabilities Edu-
 17 cation Act.

18 (j) CONSULTATION WITH INDIAN TRIBES.—In car-
 19 rying out subsection (a), the Secretary shall, in a timely
 20 manner, meaningfully consult, engage, and cooperate with
 21 Indian tribes and their representatives to ensure notice of
 22 eligibility.

23 (k) DEFINITIONS.—In this section:

24 (1) ELEMENTARY OR SECONDARY SCHOOL.—

25 The term “elementary or secondary school” means a

1 public elementary and secondary school as such term
2 is defined in section 8101 of the Elementary and
3 Secondary Education Act of 1965 (20 U.S.C. 7801).

4 (2) EVIDENCE-BASED.—The term “evidence-
5 based” has the meaning given such term in section
6 8101(21)(A)(i) of the Elementary and Secondary
7 Education Act of 1965 (20 U.S.C. 7801(21)(A)(i)).

8 (3) SCHOOL LEADER.—The term “school lead-
9 er” has the meaning given such term in section
10 8101 of the Elementary and Secondary Education
11 Act of 1965 (20 U.S.C. 7801).

12 (4) SECRETARY.—The term “Secretary” means
13 the Secretary of Education.

14 (5) SPECIALIZED INSTRUCTIONAL SUPPORT
15 PERSONNEL.—The term “specialized instructional
16 support personnel” has the meaning given such term
17 in 8101 of the Elementary and Secondary Education
18 Act of 1965 (20 U.S.C. 7801).

19 (l) AUTHORIZATION OF APPROPRIATIONS.—There is
20 authorized to be appropriated to carry out this section,
21 such sums as may be necessary for each of fiscal years
22 2019 through 2023.

1 **SEC. 515. NATIONAL CHILD TRAUMATIC STRESS INITIA-**
2 **TIVE.**

3 Section 582(j) of the Public Health Service Act (42
4 U.S.C. 290hh–1(j)) is amended by striking “\$46,887,000
5 for each of fiscal years 2018 through 2022” and inserting
6 “\$53,887,000 for each of fiscal years 2019 through
7 2023”.

○